Teligent (TLGTQ) 10-Q/A 12 Dec 18 2018 Q2 Quarterly report (amended) Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 06, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	Teligent, Inc.
Entity Central Index Key	352,998
Document Period End Date	Jun. 30, 2018
Entity Filer Category	Accelerated Filer
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2,018
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	Restatement of June 30, 2018 10-Q to correct the accounting for the early and partial extinguishment of the 3.75% Company’s Convertible Senior Notes due 2019 (the “2019 Notes”) that resulted from the separate exchange agreements entered into with certain holders of the 2019 Notes in April 2018 as well as certain out of period accounting errors, which management believes are immaterial on an individual and aggregate basis to the Company’s unaudited interim condensed consolidated financial statements for the three and six-month periods ended June 30, 2018.
Trading Symbol	TLGT
Entity Common Stock, Shares Outstanding		53,537,888

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 13,675	$ 26,692
Accounts receivable, net	16,081	12,742
Inventories, net	17,575	16,075
Prepaid expenses and other receivables	2,206	3,622
Total current assets	49,537	59,131
Property, plant and equipment, net	83,290	68,355
Intangible assets, net	52,930	56,017
Goodwill	445	471
Other assets	577	611
Total assets	186,779	184,585
Current liabilities:
Accounts payable	8,771	10,595
Accrued expenses	9,269	8,101
Total current liabilities	18,040	18,696
2021 Term Loan, net of debt discount and debt issuance costs (face of $15,000 as of June 30, 2018)	14,198	0
Convertible 3.75% Senior Notes, net of debt discount and debt issuance costs (face of $68,660 and $143,750 as of June 30, 2018 and December 31, 2017, respectively)	60,312	120,977
Convertible 4.75% Senior Notes, net of debt discount and debt issuance costs (face of $75,090 as of June 30, 2018)	55,369	0
Deferred tax liability	148	159
Total liabilities	148,067	139,832
Commitments and Contingencies
Stockholders’ equity:
Common stock, $0.01 par value, 100,000,000 shares authorized; 53,512,888 and 53,400,281 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively	554	554
Additional paid-in capital	118,524	106,312
Accumulated deficit	(78,015)	(60,094)
Accumulated other comprehensive loss	(2,351)	(2,019)
Total stockholders’ equity	38,712	44,753
Total liabilities and stockholders' equity	$ 186,779	$ 184,585

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	53,512,888	53,400,281
Common stock, shares outstanding (in shares)	53,512,888	53,400,281
Term Loan 2021
Face amount of the Notes	$ 15,000,000
Convertible Note 2019
Stated interest rate	3.75%	3.75%
Face amount of the Notes	$ 68,660,000	$ 143,750,000
Convertible Note 2023
Stated interest rate	4.75%	4.75%
Face amount of the Notes	$ 75,090,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues:
Revenue, net	$ 16,249	$ 16,432	$ 30,794	$ 34,095
Costs and expenses:
Cost of revenues	11,465	8,395	20,790	15,124
Selling, general and administrative expenses	5,727	4,706	11,087	9,005
Product development and research expenses	3,967	5,113	7,358	8,781
Total costs and expenses	21,159	18,214	39,235	32,910
Operating income (loss)	(4,910)	(1,782)	(8,441)	1,185
Other Income (Expense):
Foreign currency exchange (loss) gain	(3,220)	3,822	(1,895)	4,901
Debt partial extinguishment of Convertible 3.75% Senior Notes	(2,467)	0	(2,467)	0
Interest and other expense, net	(2,499)	(2,936)	(5,071)	(6,068)
(Loss) income before income tax expense	(13,096)	(896)	(17,874)	18
Income tax expense	23	23	47	106
Net loss	$ (13,119)	$ (919)	$ (17,921)	$ (88)
Basic and diluted loss per share (in dollars per share)	$ (0.25)	$ (0.02)	$ (0.34)	$ 0
Weighted average shares of common stock outstanding:
Basic and diluted shares (in shares)	53,510,712	53,304,407	53,484,756	53,250,109

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Parenthetical)	Jun. 30, 2018	Dec. 31, 2017
Convertible Note 2019
Stated interest rate	3.75%	3.75%

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement of Comprehensive Income [Abstract]
Net loss	$ (13,119)	$ (919)	$ (17,921)	$ (88)
Other comprehensive loss, net of tax;
Foreign currency translation adjustment	(28)	(163)	(332)	(245)
Other comprehensive loss	(28)	(163)	(332)	(245)
Comprehensive loss	$ (13,147)	$ (1,082)	$ (18,253)	$ (333)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2018 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Convertible Note 2023	Convertible Note 2023Additional Paid-in Capital
Balance (in shares) at Dec. 31, 2017		53,400,281
Balance at Dec. 31, 2017	$ 44,753	$ 554	$ 106,312	$ (2,019)	$ (60,094)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation expense	1,165		1,165
Stock options exercised (in shares)		11,000
Stock options exercised	12		12
Issuance of stock for vested restricted stock units (in shares)		101,607
Fair value of conversion feature on Convertible 4.75% Senior Notes						$ 18,637	$ 18,637
Partial extinguishment of equity component of Convertible 3.75% Senior Notes	7,600					$ (7,602)	$ (7,602)
Cumulative translation adjustment	(332)			(332)
Net loss	(17,921)
Balance (in shares) at Jun. 30, 2018		53,512,888
Balance at Jun. 30, 2018	$ 38,712	$ 554	$ 118,524	$ (2,351)	$ (78,015)

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)	Jun. 30, 2018	Dec. 31, 2017
Convertible Note 2023
Stated interest rate	4.75%	4.75%
Convertible Note 2019
Stated interest rate	3.75%	3.75%

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net loss	$ (17,921)	$ (88)
Reconciliation of net loss to net cash used in operating activities
Depreciation and amortization of fixed assets	1,133	822
Provision for bad debt expense	811	26
Provision for write down of inventory	1,154	918
Stock based compensation	1,103	1,739
Amortization of debt issuance costs	505	456
Amortization of intangible assets	1,550	1,396
Foreign currency exchange loss (gain)	1,895	(4,901)
Partial extinguishment of Convertible 3.75% Senior Notes	2,467	0
Amortization of debt discount	4,422	4,183
Loss on impairment of intangible assets	22	0
Changes in operating assets and liabilities
Accounts receivable	(4,227)	(4,008)
Inventories	(2,816)	(2,554)
Prepaid expenses and other current receivables	1,443	(208)
Other assets	35	20
Accounts payable and accrued expenses	(4,086)	892
Net cash used in operating activities	(12,510)	(1,307)
Cash flows from investing activities:
Capital expenditures	(12,523)	(15,286)
Net cash used in investing activities	(12,523)	(15,286)
Cash flows from financing activities:
Proceeds from exercise of common stock options	12	267
Proceeds from 2021 Term Loan	15,000	0
Debt fees on Convertible 4.75% Senior Notes and 2021 Term Loan	(2,457)	0
Net cash provided by financing activities	12,555	267
Effect of exchange rate on cash and cash equivalents	(540)	536
Net decrease in cash, cash equivalents and restricted cash	(12,478)	(16,326)
Cash, cash equivalents and restricted cash at beginning of period	27,165	66,481
Cash, cash equivalents and restricted cash at end of period	14,147	50,691
Supplemental Cash flow information:
Cash payments for interest	2,475	2,695
Cash payments for income taxes	48	93
Non cash operating, investing and financing transactions:
Acquisition of capital expenditures in accounts payable and accrued expenses	3,042	4,260
Capitalized interest in capital expenditures	477	0
Capitalized stock compensation in capital expenditures	$ 63	$ 66

CONDENSED CONSOLIDATED STATEM_7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - Senior Notes	Jun. 30, 2018	Jun. 30, 2017
3.75% Senior Note
Stated interest rate	3.75%	3.75%
4.75% Senior Note
Stated interest rate	4.75%	4.75%

Restatement of Previously Issue

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2018
Accounting Changes and Error Corrections [Abstract]
Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements	Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements Subsequent to the issuance of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, management determined a material adjustment was needed to correct the accounting for the early and partial extinguishment of the Company’s Convertible 3.75% Senior Notes due 2019 (the “2019 Notes”) that resulted from the separate exchange agreements entered into with certain holders of the 2019 Notes in April 2018 (see Note 7 for further information regarding the 2019 Notes). Accordingly, the accompanying unaudited interim condensed consolidated financial statements of the Company for the three and six-months ended June 30, 2018, and the related notes hereto, have been restated to correct this error. In addition, the Company has elected to correct certain other accounting errors, which management believes are immaterial on an individual and aggregate basis to the Company’s unaudited interim condensed consolidated financial statements for the three and six-months ended June 30, 2018 and 2017. The correction of all the foregoing accounting errors is collectively referred to herein as "the Restatement". A summary of the correction of these accounting errors, and their impact on the unaudited condensed consolidated financial statements for the three and six-month periods ended June 30, 2018 and June 30, 2017, are as follows: (1) In April 2018, the Company entered into separate exchange agreements with certain holders of the 2019 Notes to exchange an aggregate of $75.1 million of the 2019 Notes for an equal amount of newly issued Convertible 4.75% Senior Notes due 2023. The effect of this exchange was accounted for as an early and partial extinguishment of $75.1 million of the 2019 Notes, whereby an aggregate of approximately $10.1 million unamortized debt discount and financing costs associated with the 2019 Notes were written off and recognized as non-cash interest expense. Upon further analysis, management determined that the exchange of $75.1 million of 2019 Notes should have been accounted for by applying the cash conversion guidance prescribed by ASC 470-20, which requires, upon derecognition, among other things, an allocation of the fair value of the consideration transferred at settlement between (i) the extinguished liability component and (ii) the reacquired equity component. Accordingly, the accompanying unaudited interim condensed consolidated financial statements as of and for the three and six-month periods ended June 30, 2018 have been restated to reflect the application of this guidance in ASC 470-20 by decreasing the amount of non-cash interest expense recognized during the three and six-month periods ended June 30, 2018 by approximately $7.6 million , increasing the Company’s outstanding Convertible 4.75% Senior Notes, net of debt discount and debt issuance costs, as of June 30, 2018 by approximately $0.4 million , and decreasing additional paid-in capital as of June 30, 2018 by approximately $8.0 million . (2) The Company identified approximately $0.3 million of uncollectible accounts receivable related to certain prior period pricing and shipment errors. Accordingly, the accompanying unaudited interim condensed consolidated financial statements as of and for the three and six-month periods ended June 30, 2018 has been revised to reflect the write-off of these out of period amounts by decreasing Revenue, net by approximately $0.3 million for the three and six-month periods ended June 30, 2018, respectively, decreasing Accounts Receivable, net, by $0.4 million and increasing Accounts Payable by $0.1 million as of June 30, 2018. (3) The Company identified approximately $0.2 million of uncollectible accounts receivable related to pricing and shipment errors that were previously written off and incorrectly classified within as Selling, General and Administrative Expenses rather than a reduction of Revenue, net. Accordingly, the accompanying unaudited interim condensed consolidated financial statements as of and for the three and six-month periods ended June 30, 2018 has been revised to reflect the proper classification of this amount by decreasing Revenues, net and decreasing Selling, General and Administrative Expenses by approximately $0.2 million for the three and six-month periods ended June 30, 2018, respectively. (4) The Company identified approximately $0.3 million of costs that were previously incurred and should have been capitalized to Property, Plant and Equipment, net rather than recognized as Cost of Revenues. Accordingly, the accompanying unaudited interim condensed consolidated financial statements as of and for the three and six-month periods ended June 30, 2018 has been revised to reflect the proper classification of this out of period amount by increasing Property, Plant, and Equipment as of June 30, 2018 and reducing Cost of Revenues for the three and six-month periods ended June 30, 2018 by approximately $0.3 million , respectively. The effect on depreciation expense associated with the correction of this error was nil. (5) The Company pays wholesalers certain fees associated with the sale of the Company’s product. The payment of these fees had been historically classified by the Company as cost of revenues and accrued expenses prior to the adoption of ASC 606, Revenue from Contracts with Customers. As disclosed in Note 4, the Company adopted ASC 606 on January 1, 2018 using the modified retrospective method, at which time the Company began classifying the payment of wholesaler fees as a reduction of revenue and accounts receivable. Upon further analysis, however, management determined that these fees should have always been classified as a reduction of revenue and accounts receivable, rather than as costs of revenues and accrued expenses, because the services provided by the Company’s wholesalers cannot generally be provided by third parties and the underlying fees are not specifically identifiable from other services. As a result, the accompanying unaudited interim condensed consolidated financial statements as of and for the three and six-month periods ended June 30, 2017 has been revised to correct the presentation of wholesaler fees as a reduction of revenue rather than as cost of revenues. The correction of this error resulted in a reduction of revenue of approximately of $2.0 million and $4.2 million , respectively, for the three and six-month periods ended June 30, 2017. In addition, the correction of this error resulted in a reduction in accounts receivable and decrease in accrued expenses of approximately $5.4 million , respectively, as of June 30, 2017 and $7.0 million , respectively, as of December 31, 2017. (6) Prior to the adoption of ASC 606, the Company classified Medicaid, Medicare and other rebates (the “Rebates”) as a reduction of accounts receivable, whereas subsequent to adoption of ASC 606 the Company began classifying the Rebates as accrued expenses. Upon further analysis, management determined that the Rebates should have always been classified as accrued expenses because their terms require cash settlement and are payable to third parties that are other than the Company’s customer. The correction of this error resulted in an increase in accounts receivable and increase in accrued expenses of $2.5 million , respectively, as of June 30, 2017 and $1.6 million , respectively, as of December 31, 2017. The following tables summarize the effect of the Restatement on the Company's unaudited interim condensed consolidated financial statements as of and for the three and six-months ended June 30, 2017 (in thousands): CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three months ended June 30, 2018 Six months ended June 30, 2018 As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Revenues: Revenues, net $ 16,751 $ (502 ) (2), (3) $ 16,249 $ 31,296 $ (502 ) (2), (3) $ 30,794 Costs and Expenses: Cost of revenues 11,728 (263 ) (4) 11,465 21,053 (263 ) (4) 20,790 Selling, general and administrative expenses 5,961 (234 ) (3) 5,727 11,321 (234 ) (3) 11,087 Total costs and expenses 21,656 (497 ) 21,159 39,732 (497 ) 39,235 Operating loss (4,905 ) (5 ) (4,910 ) (8,436 ) (5 ) (8,441 ) Other Income (Expense): Partial extinguishment of Convertible 3.75% Notes (10,069 ) 7,602 (1) (2,467 ) (10,069 ) 7,602 (1) (2,467 ) Loss before income tax expense (20,693 ) 7,597 (13,096 ) (25,471 ) 7,597 (17,874 ) Net loss $ (20,716 ) $ 7,597 $ (13,119 ) $ (25,518 ) $ 7,597 $ (17,921 ) Basic and diluted loss per share $ (0.39 ) $ 0.14 $ (0.25 ) $ (0.48 ) $ 0.14 $ (0.34 ) CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, 2018 June 30, 2018 As Previously Reported Adjustments As Restated Accounts receivable, net $ 16,232 $ (151 ) (2) $ 16,081 Total current assets 49,688 (151 ) 49,537 Property, plant and equipment 83,027 263 (4) 83,290 Total assets $ 186,667 $ 112 $ 186,779 Current liabilities: Accounts payable $ 8,654 $ 117 (2) $ 8,771 Total current liabilities 17,923 117 18,040 Convertible 4.75% Senior Notes, net of debt discount and debt issuance costs (face of $75,090, as of June 30, 2018) 54,963 406 (1) 55,369 Total liabilities 147,544 523 148,067 Additional paid in capital 126,532 (8,008 ) (1) 118,524 Accumulated deficit (85,612 ) 7,597 (78,015 ) Total stockholders’ equity 39,123 (411 ) 38,712 Total liabilities and stockholders' equity $ 186,667 $ 112 $ 186,779 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) Three months ended June 30, 2018 Six months ended June 30, 2018 As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Net loss $ (20,716 ) $ 7,597 (1),(2),(3),(4) $ (13,119 ) $ (25,518 ) $ 7,597 (1),(2),(3),(4) $ (17,921 ) Comprehensive loss $ (20,744 ) $ 7,597 (1),(2),(3),(4) $ (13,147 ) $ (25,850 ) $ 7,597 (1),(2),(3),(4) $ (18,253 ) CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Six months ended June 30, 2018 As Previously Reported Adjustments As Restated Net loss $ (25,518 ) $ 7,597 (1),(2),(3),(4) $ (17,921 ) Additional Paid in Capital 126,532 (8,008 ) (1) 118,524 Total Stockholder's Equity $ 39,123 $ (411 ) (1),(2),(3),(4) $ 38,712 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Six months ended June 30, 2018 As Previously Reported Adjustments As Restated Cash flows from operating activities: Net income (loss) $ (25,518 ) $ 7,597 (1),(2),(3),(4) $ (17,921 ) Stock based compensation 1,113 (10 ) (4) 1,103 Partial extinguishment of Convertible 3.75% Senior Notes 10,069 (7,602 ) (1) 2,467 Changes in operating assets and liabilities: Accounts receivable 1,023 (5,250 ) (2),(5), (a) (4,227 ) Accounts payable and accrued expenses (9,604 ) 5,518 (5), (a) (4,086 ) Net cash provided by operating activities (12,763 ) 253 (12,510 ) Cash flows from investing activities: Capital expenditures (12,270 ) (253 ) (4) (12,523 ) Net cash used in investing activities (12,270 ) (253 ) (12,523 ) Non cash investing and financing transactions: Capitalized stock compensation in capital expenditures 53 10 (4) 63 Condensed Consolidated Statements of Operations Three Months Ended June 30, 2017 Six Months Ended June 30, 2017 As Previously Reported Adjustments As Revised As Previously Reported Adjustments As Revised Revenue, net $ 18,408 $ 1,976 (5) $ 16,432 $ 38,299 $ 4,204 (5) $ 34,095 Cost of revenues 10,371 1,976 (5) 8,395 19,328 4,204 (5) 15,124 Total costs and expenses 20,190 1,976 (5) 18,214 37,114 4,204 (5) 32,910 Condensed Consolidated Balance Sheet Condensed Consolidated Balance Sheet June 30, 2017 December 31, 2017 As Previously Reported Adjustments As Revised As Previously Reported Adjustments As Revised Accounts receivable, net $ 27,272 $ 2,853 (5),(6) $ 24,419 $ 18,143 $ 5,401 (5),(6) $ 12,742 Total current assets 95,009 2,853 (5),(6) 92,156 64,532 5,401 (5),(6) 59,131 Total assets 196,385 2,853 (5),(6) 193,532 189,986 5,401 (5),(6) 184,585 Accrued expenses 12,019 2,853 (5),(6) 9,166 13,502 5,401 (5),(6) 8,101 Total current liabilities 21,728 2,853 (5),(6) 18,875 24,097 5,401 (5),(6) 18,696 Total liabilities 137,977 2,853 (5),(6) 135,124 145,233 5,401 (5),(6) 139,832 Total liabilities and stockholders' equity 196,385 2,853 (5),(6) 193,532 189,986 5,401 (5),(6) 184,585 Condensed Consolidated Statement of Cash Flows Six Months Ended June 30, 2017 As Previously Reported Adjustments As Revised Cash flows from operating activities Accounts receivable $ (5,530 ) $ (1,522 ) (5),(6) $ (4,008 ) Accounts payable and accrued expenses 2,414 1,522 (5),(6) 892

Nature of the Business and Liqu

Nature of the Business and Liquidity	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Liquidity	Nature of the Business and Liquidity Nature of the Business Teligent, Inc. and its subsidiaries (collectively the “Company”), is a specialty generic pharmaceutical company. Our mission is to become a leader in the specialty generic pharmaceutical market in alternate dosage forms. Under our own label, we currently market and sell generic topical and generic and branded generic injectable pharmaceutical products in the United States and Canada. In the United States, we currently market 28 generic topical pharmaceutical products and four branded generic injectable pharmaceutical products. In Canada, we sell over 30 generic and branded generic injectable products and medical devices. Generic pharmaceutical products are bioequivalent to their brand name counterparts. We also provide contract manufacturing services to the pharmaceutical, over-the-counter ("OTC"), and cosmetic markets. We operate our business under one reportable segment. Our common stock is traded on the NASDAQ Global Select Market under the trading symbol “TLGT.” Our principal executive office, laboratories and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey. We have additional offices located in Iselin, New Jersey, Toronto, Canada, and Tallinn, Estonia. Liquidity Our capital resources were comprised of cash and cash equivalents of $13.7 million and $26.7 million as of June 30, 2018 and December 31, 2017, respectively. The reduction in our cash during the six months ended June 30, 2018 was largely due to our additional year-to-date investment of $12.5 million in the Company's new manufacturing facility located in Buena, New Jersey, along with the timing of our accounts receivable collections and expense payments associated with our launch of five new products in the U.S. market. In addition, we had an accumulated deficit of $78.0 million as of June 30, 2018 and incurred a $17.9 million net loss and used $12.5 million in net cash from operating activities during the six months ended June 30, 2018. Our liquidity needs have typically arisen from the funding of our manufacturing facility, research and development programs and the launch of new products. In the past, we have met these cash requirements through cash inflows from operations, working capital management, and proceeds from our Convertible 3.75% Senior Notes ("2019 Notes"). The 2019 Notes were issued in December 2014 and are due in December 2019. On April 27, 2018, the Company entered into separate exchange agreements with certain holders of the 2019 Notes. The agreements gave the holder the right to exchange in aggregate $75.1 million of the 2019 Notes for $75.1 million of new Convertible 4.75% Senior Notes due 2023 (“2023 Notes”). Additional information is provided in Note 7. We expect to continue to incur significant expenditures for the development of new products in our pipeline, and the manufacturing and sales and marketing of our existing product. While we rely heavily on cash flows from operating activities and borrowings and from outside sources to execute our operational strategy and meet our financial commitments and other short-term financial needs, we cannot be certain that sufficient capital will be generated through operations or will be available to the Company to the extent required and on acceptable terms. In order to continue normal business operations and execution of the Company’s growth strategy, the Company has and will continue to exercise its ability to significantly defer or reduce planned discretionary investments in research and development and capital projects or seek other financing alternatives. Other financing alternatives may include raising additional capital through the sale of its equity, a strategic alliance with a third party or securing debt. If additional acquisition and growth opportunities arise, external financing will be required. On May 4, 2018, the Company filed Form S-3 under the Securities Act of 1933. The S-3 registration allows the Company to issue, from time to time and at prices to be determined at or prior to the offering, up to $50.0 million of any combination of the securities described in the prospectus, either individually or in units should the need to raise cash arise. On June 1, 2018, the Company secured a term loan ("2021 Term Loan") for $25.0 million to support the operations of the business. The first $15.0 million of loan proceeds was received on June 1, 2018. The remaining loan proceeds of $10.0 million was received on July 16, 2018. The Company is currently evaluating alternative financing methods. As the Company continues to review its capital and debt structure, there can be no assurance that a strategic alliance or debt financing will be available on terms acceptable to the Company, or at all. The board of directors and management of the Company intend to exercise all options available in order to enable the Company to support its current growth strategy and operations beyond December 2019. Out of Period Adjustments For the three and six months ended June 30, 2018, the Company recorded the following adjustments (in thousands) related to prior periods. The net impact of the adjustments on any prior annual or interim periods financial statements was not significant. There were no adjustments related to prior periods recorded for the three and six months ended June 30, 2017. Three months ended Six months ended June 30, 2018 June 30, 2018 Wholesale fees (Revenue) $ 856 $ 1,218 Medicaid (Revenue) 297 297 Pricing and shipment adjustment (Revenue) (2), (3) (502 ) (502 ) Sales return reserve (Revenue) — (577 ) Inventory adjustments (Cost of revenues) — 95 Capitalization of property, plant and equipment (Cost of revenues) (4) 263 263 Bad debt expense (Selling, general and administrative expenses) (578 ) (578 ) $ 336 $ 216

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Teligent, Inc. and its wholly-owned and majority-owned subsidiaries. All inter-company accounts and transactions have been eliminated. The Company consolidated the following entities: Igen, Inc., Teligent Pharma. Inc., Teligent Luxembourg S.à.r.l., Teligent OÜ, Teligent Canada Inc., and Teligent Jersey Limited., in addition to the following inactive entities: Microburst Energy, Inc., Blood Cells, Inc. and Flavorsome, Ltd. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the historical valuation of the derivative liability, sales returns and allowances, allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related valuation allowances, stock based compensation, the assessment for the impairment of long-lived assets (including intangibles, goodwill and property, plant and equipment), property, plant and equipment and legal accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates. Cash Equivalents The Company considers all highly liquid instruments purchased with the original maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. Cash and cash equivalents include cash on hand and bank demand deposits used in the Company’s cash management program. The Company has restricted cash, consisting of escrow accounts and letter of credits, which is included within other assets on the Condensed Consolidated Balance Sheet. The Company also presents restricted cash with cash and cash equivalents in the Condensed Consolidated Statement of Cash Flows. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the Consolidated Balance Sheet to the total amounts in the Consolidated Statement of Cash Flows as follows (in thousands): June 30, 2018 December 31, 2017 June 30, 2017 December 31, 2016 Cash and cash equivalents $ 13,675 $ 26,692 $ 50,216 $ 66,006 Restricted cash in other assets 472 473 475 475 Cash, cash equivalents and restricted cash in the statement of cash flows $ 14,147 $ 27,165 $ 50,691 $ 66,481 Stock Based Compensation ASC 718-10 defines the fair-value-based method of accounting for stock-based employee compensation plans and transactions used by the Company to account for its issuances of equity instruments to record compensation cost for stock-based employee compensation plans at fair value as well as to acquire goods or services from non-employees. Transactions in which the Company issues stock-based compensation to employees, directors and advisors and for goods or services received from non-employees are accounted for based on the fair value of the equity instruments issued. The Company utilizes pricing models in determining the fair values of options, restricted stock units ("RSU's") and warrants issued as stock-based compensation. These pricing models utilize the market price of the Company’s common stock and the exercise price of the option or warrant, as well as time value and volatility factors underlying the positions. Stock-based compensation expense is recognized over the requisite service period of the award, which usually coincides with the vesting period of the grant. Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, trade receivables, notes payable, accounts payable and other accrued liabilities at June 30, 2018 approximate their fair value for all periods presented. As of June 30, 2018 , the net carrying value of the 2019 Notes and 2023 Notes (collectively the "Notes" and discussed in Note 7) was approximately $115.7 million compared to their face value of $143.75 million . This variance is due to the conversion feature in the Notes rather than to changes in market interest rates. The Notes carry a fixed interest rate and therefore do not subject the Company to interest rate risk. As of June 30, 2018, the net carrying value of the 2021 Term Loan (discussed in Note 7) was approximately $14.2 million compared to the face value of $15.0 million . The variance is due to debt discount and debt financing costs. The 2021 Term Loan bears interest at a rate of LIBOR plus 9% , and is therefore subject to market risk. Loss Per Share Basic loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Potential dilutive common stock equivalents include shares issuable upon the conversion of the 2019 and 2023 Notes, the exercise of options, and the vesting RSU's. For the three and six months ended June 30, 2018 , the potential dilutive common stock equivalents have been excluded from the computation of diluted loss per share, as their effect would have been anti-dilutive. (in thousands except shares and per share data) Three months ended June 30, Six months ended June 30, 2018 (Restated) 2017 2018 (Restated) 2017 Basic loss per share computation: Net loss - basic and diluted $ (13,119 ) $ (919 ) $ (17,921 ) $ (88 ) Weighted average common shares - basic and diluted 53,510,712 53,304,407 53,484,756 53,250,109 Basic and diluted loss per share $ (0.25 ) $ (0.02 ) $ (0.34 ) $ 0.00 Revenue Recognition The Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. The Company's revenue is recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. The Company derives its revenues from three types of transactions: sales of its own pharmaceutical products (Company product sales), sales of manufactured product for its customers (contract manufacturing sales), and research and product development services performed for third parties. Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each. Taxes collected from customers and remitted to government authorities and that are related to the sales of the Company’s products are excluded from revenues. See more detailed information in Note 4. Adoption of ASC Topic 606, "Revenue from Contracts with Customers” In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” The standard, including subsequently issued amendments, replaces most existing revenue recognition guidance in U.S. GAAP. The key focus of the new standard is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performed a comprehensive review of its existing revenue arrangements as of January 1, 2018 following the aforementioned five-step model. Based on the Company's analysis, there were no changes identified that impacted the amount or timing of revenues recognized under the new guidance as compared to the previous guidance. Additionally, the Company's analysis indicated that there were no changes to how costs to obtain and fulfill our customer contracts would be recognized under the new guidance as compared to the previous guidance. The impact of the adoption of this standard on the Company's Condensed Consolidated Balance Sheet, Condensed Consolidated Statement of Operations, and Condensed Consolidated Statement of Cash Flows was not material. The adoption of the new guidance impacted the way the Company analyzes, documents, and discloses revenue recognition under customer contracts beginning on January 1, 2018 and resulted in additional disclosures in the Company's financial statements. Property, Plant and Equipment Depreciation and amortization of property, plant and equipment is provided for under the straight-line method over the assets’ estimated useful lives as follows: Useful Lives Buildings and Improvements 10 - 40 years Machinery and Equipment 5 - 15 years Computer Hardware and Software 3 - 5 years Furniture Fixtures 5 years Leasehold improvements are amortized over the shorter of estimated useful life or the lease term. Repair and maintenance costs are charged to operations as incurred while major improvements are capitalized. Construction in progress ("CIP") costs are amortized based on the asset class when they are put into service. When assets are retired or disposed, the related cost and accumulated depreciation thereon are removed and any gains or losses are included in operating results. Concentration of Credit Risk Major customers of the Company are defined as those constituting greater than 10% of our total revenue. For the three months ended June 30, 2018 , two of the Company’s customers accounted for 49% of the Company’s revenue, consisting of 35% and 14% , respectively. For the three months ended June 30, 2017 , three of the Company’s customers accounted for 50% of the Company’s revenue, consisting of 26% , 10% and 14% , respectively. For the six months ended June 30, 2018 , two of the Company's customers accounted for 48% of the Company's revenue, consisting of 35% and 13% , respectively. For the six months ended June 30, 2017 , three of the Company's customers accounted for 52% of the Company's revenue, consisting of 26% , 13% and 13% , respectively. Accounts receivable related to the Company’s major customers comprised 49% of all accounts receivable as of June 30, 2018 , and 67% of all accounts receivable as of June 30, 2017 . The loss of one or more of these major customers could have a significant impact on our revenues and harm our business and results of operations . For the three months ended June 30, 2018 , domestic net revenues were $11.4 million and foreign net revenues were $4.9 million . For the six months ended June 30, 2018 , domestic net revenues were $21.6 million and foreign net revenues were $9.2 million . As of June 30, 2018 , domestic assets were $125.9 million and foreign assets were $60.9 million . For the three months ended June 30, 2017 , domestic net revenues were $13.0 million and foreign net revenues were $3.4 million . For the six months ended June 30, 2017 , domestic net revenues were $27.8 million and foreign net revenues were $6.3 million . As of June 30, 2017 , domestic assets were $124.8 million and foreign assets were $68.7 million . Foreign Currency Translation The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in Accumulated Other Comprehensive (Loss) ("AOCI") and reflected as a separate component of equity. For those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Foreign currency exchange gain line item under the Other income (expense), net section of the Condensed Consolidated Statement of Operations. Debt Issuance Costs Expenses related to debt financing activities are capitalized and amortized on an effective interest method, over the term of the loan and are to be netted against the carrying value of the financial liability, as required by ASU 2015-3. This standard aligns the treatment of debt issuance costs and debt discounts in that both reduce the carrying value of the liability. Amortization of debt issuance costs is to be recorded as interest expense on the Condensed Consolidated Statement of Operations. Adoption of Other Recent Accounting Pronouncements In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): "Restricted Cash (a consensus of the FASB Emerging Issues Task Force)". The update addresses the diversity in the industry with respect to classification and presentation of changes in restricted cash on the statement of cash flows. These amendments require that a statement of cash flows explain the restricted cash change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The amendments in this update were effective for fiscal years beginning after December 15, 2017 for public business entities, including interim periods within those fiscal years. For the Company, the amendments were effective January 1, 2018. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): “Clarifying the Definition of a Business”. The update clarifies the definition of a business, specifically for companies to better evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update were effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those annual periods. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-03, Accounting Changes and Error Corrections (Topic 250) and Investments—Equity Method and Joint Ventures (Topic 323): “Amendments to SEC Paragraphs Pursuant to Staff Announcements at the September 22, 2016 and November 17, 2016 EITF Meetings”. The update shows amendments to two SEC Announcements made late in 2016 regarding four specific standards as follows: ASU 2014-09, Revenue from Contracts with Customers (Topic 606), ASU 2016-02, Leases (Topic 842), ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), and ASU 2014-01, Investments - Equity Method and Joint Ventures (Topic 323). The amendments in this update require changes to the U.S. GAAP Financial Reporting Taxonomy and the changes will be incorporated into the proposed 2018 Taxonomy which are available for public comment and finalized as part of the annual release process. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its consolidated financial statements. In February 2017, the FASB issued ASU 2017-05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): “Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets”. This update addresses guidance for partial sales of nonfinancial assets. It affects (i) an entity that enters into a contract to transfer to a customer a nonfinancial asset, group of nonfinancial assets, or ownership interest in a consolidated subsidiary that is not a business or nonprofit entity, (ii) an entity that historically had transactions within the scope of the real estate-specific derecognition guidance, and (iii) an entity that contributes nonfinancial assets that are not a business or a nonprofit activity to a joint venture or other noncontrolled investee. The amendments were effective at the same time as the amendments in ASU 2014-09. Therefore, for the Company, the amendments were effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Public entities may apply the guidance earlier but only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company does not currently expect to enter into any such nonfinancial asset or ownership interest in its consolidated subsidiaries agreements but will refer to the guidance in ASU 2017-05 should that occur. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): “Scope of Modification Accounting”. This update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments affect any entity that changes the terms or conditions of a share-based payment award. The amendments are effective for fiscal years beginning after December 15, 2017. For the Company, the amendments were effective January 1, 2018. The Company has not made any changes to the terms or conditions of share-based payment awards but will refer to the guidance in ASU 2017-09 should that occur. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its consolidated financial statements. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): “Recognition and Measurement of Financial Assets and Financial Liabilities”. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. The Company is reviewing all lease agreements inclusive of supplier agreements. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): “Simplifying the Test for Goodwill Impairment”. The update simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. It affects public entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill. A public entity that is a U.S. Securities and Exchange Commission ("SEC") filer should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. For the Company, the amendments are effective January 1, 2020. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. In February 2018, the FASB issued ASU 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income,” which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. This guidance is effective for all entities for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. The amendments in ASU 2018-02 should be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The adoption of this guidance is not expected to have a material impact on the Company's Consolidated Financial Statements and related disclosures.

Revenues, Recognition and Allow

Revenues, Recognition and Allowances	6 Months Ended
	Jun. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenues, Recognition and Allowances	Revenues, Recognition and Allowances Revenue Recognition As of January 1, 2018, the Company adopted the ASC 606 guidance for revenue recognition for contracts, using the modified retrospective method. The implementation of this guidance had no material impact on the measurement or recognition of revenue from customer contracts of prior periods. Upon adoption of this new guidance, the Company recognizes revenue using the following five steps: • Identification of the contract, or contracts, with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price, including the identification and estimation of variable consideration; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when we satisfy a performance obligation. The Company derives its revenues from three types of transactions: sales of its own pharmaceutical products (Company product sales), sales of manufactured product for its customers (contract manufacturing sales), and research and product development services performed for third parties. Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience as well as applicable information currently available. Company Product Sales Revenue from Company product sales is recognized upon transfer of control of a product to a customer at a point in time, generally as the Company's products are sold on an FOB destination basis and because inventory risk and risk of ownership passes to the customer upon delivery. Company product sales are recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns (collectively, sales returns and allowances or “SRA”). Contract Manufacturing Sales The Company recognizes revenue for contract manufacturing sales upon transfer of control of a product to a customer, which is generally upon shipment of products. However, with the new adoption of revenue recognition for contracts, the Company recognizes the revenue over time, rather than upon shipment. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. Contract manufacturing sales are recognized net of accruals for cash discounts and returns which are established at the time of sale, and are included in revenues, net in the Company's Condensed Consolidated Statement of Operations. Research and Development Services and Other Income The Company establishes agreed upon product development agreements with its customers to perform product development services. Revenues are recognized in accordance with the agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Other types of revenue include royalty or licensing revenue, and would be recognized over time, or at a point in time, based upon the contractual term upon completion of the earnings process. Judgments are required to evaluate contingencies such as potential variances in schedule and the costs, the impact of change orders, liability claims, contract disputes and achievement of contractual performance standards. Revenues by Transaction Type The Company operates in one reportable segment and, therefore, the results of the Company's operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting for the chief decision makers. Net Sales (in thousands) for the three and six months ended June 30, 2018 and 2017 were as follows (prior-period amounts are not adjusted under the modified-retrospective method of adoption): Three months ended June 30, Six months ended June 30, 2018 2017 2018 2017 Company product sales $ 14,677 $ 13,912 $ 27,913 $ 28,120 Contract manufacturing sales 1,450 2,407 2,748 5,824 Research and development services and other income 122 113 $ 133 $ 151 Revenue, net $ 16,249 $ 16,432 $ 30,794 $ 34,095 Disaggregated information for the Company product sales revenue has been recognized in the accompanying unaudited interim Condensed Consolidated Statements of Operations is presented below according to contract type (in thousands): Three months ended June 30, Six months ended June 30, Company Product Sales 2018 2017 2018 2017 Topical $ 7,888 $ 8,558 $ 15,795 $ 16,153 Injectables 6,789 5,354 12,118 11,967 Total $ 14,677 $ 13,912 $ 27,913 $ 28,120 In the six months ended June 30, 2018 , Company did not incur, and therefore did not defer, any material incremental costs to obtain contracts. Sales Returns and Allowances As is customary in the pharmaceutical industry, the Company’s product sales are subject to a variety of deductions including chargebacks, rebates, cash discounts, other allowances, and returns. Product sales are recorded net of accruals for SRA, which are established at the time of sale. The Company analyzes the adequacy of its accruals for SRA quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. These provisions are estimates based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The Company uses a variety of methods to assess the adequacy of its SRA reserves to ensure that its financial statements are fairly stated. These include periodic reviews of customer inventory data, customer contract programs, subsequent actual payment experience, and product pricing trends to analyze and validate the SRA reserves. Net Company product sales of $14.7 million and $13.9 million for the three months ended June 30, 2018 and 2017 , respectively, are included in product sales, net in the Condensed Consolidated Statements of Operations. Net Company product revenue of $ 27.9 million and $ 28.1 million for the six months ended June 30, 2018 and 2017 , respectively, are included in product sales, net in the Condensed Consolidated Statements of Operations. Accounts receivable are presented net of SRA balances of $19.3 million and $33.7 million at June 30, 2018 and 2017 , respectively. For the six months ended June 30, 2018 , the Company recorded income of $0.8 million due to a decrease in the Medicaid reserve primarily related to finalizing the payment per the terms of the product acquisition agreement. The accrual for chargebacks is one of the Company's most significant estimates for recognition of product sales. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by its wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from its largest wholesale customers. This customer inventory information is used to establish the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent a majority of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. The rebate accrual is used for various discounts and rebates provided to customers. This account has been used for various one-time discounts given to customers. The Company reviews the percentage of products sold through these programs by reviewing chargeback data and uses the appropriate percentages to calculate the rebate accrual. Rebates are invoiced monthly or quarterly and reviewed against the accruals. Other items that could be included in accrued rebates would be price protection fees, shelf stock adjustments (SSAs), or other various amounts that would serve as one time discounts on specific products. The Company's adjustments for the deductions to gross product sales are as follows (in thousands): Three months ended June 30, Six months ended June 30, 2018 2017 2018 2017 Gross product sales $ 48,142 $ 66,744 $ 84,690 $ 121,044 Deduction to gross product sales: Chargebacks and billbacks 21,449 44,090 38,364 74,105 Wholesaler fees for service 477 1,976 1,112 4,204 Sales discounts and other allowances 11,539 6,766 17,301 14,615 Total reduction to gross product sales $ 33,465 $ 52,832 $ 56,777 $ 92,924 Company product sales, net $ 14,677 $ 13,912 $ 27,913 $ 28,120 Financing and Payment The Company's payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because the Company's customers generally pay the Company within 100 days. Costs to Obtain or Fulfill a Customer Contract Sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in selling, general and administrative expense in the Condensed Consolidated Statements of Operations. Costs related to shipping and handling is comprised of outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts with customers as fulfillment costs which are included in cost of sales in the Condensed Consolidated Statements of Operations. In connection with four of the 30 products the Company currently manufactures, markets and distributes in its own label in the U.S., in accordance with an agreement entered into in December of 2011, the Company is required to pay a royalty calculated based on net sales to one of its pharmaceutical partners. The royalty is calculated based on contracted terms of 40% of net sales for the four products, which is to be paid quarterly to the pharmaceutical partner. Accounts payable and accrued expenses include $0.6 million and $0.4 million at June 30, 2018 and 2017 , respectively, related to these royalties. Royalty expense of $0.7 million and $0.4 million was included in cost of sales in the Condensed Consolidated Statements of Operations for the three months ended June 30, 2018 and 2017 , respectively. Royalty expense of $1.5 million and $0.9 million was included in cost of sales in the Condensed Consolidated Statements of Operations for the six months ended June 30, 2018 and 2017 , respectively.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are valued at the lower of cost or net realizable value, using the first-in-first-out method and consist of the following (in thousands): June 30, 2018 December 31, 2017 (Unaudited) (Audited) Raw materials $ 10,655 $ 8,231 Work in progress 944 616 Finished goods 8,434 8,532 Inventories reserve (2,458 ) (1,304 ) Inventories, net $ 17,575 $ 16,075

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment consists of the following (in thousands): June 30, 2018 December 31, 2017 (Unaudited) (Audited) Land $ 257 $ 257 Building and improvements 17,474 8,613 Machinery and equipment 9,674 9,142 Computer hardware and software 4,059 3,244 Furniture and fixtures 553 449 Construction in progress 60,531 55,017 92,548 76,722 Less accumulated depreciation and amortization (9,258 ) (8,367 ) Property, plant and equipment, net $ 83,290 $ 68,355 The Company recorded depreciation expense of $1.1 million and $0.8 million for the six months ended June 30, 2018 and June 30, 2017 , respectively. During the three months ended June 30, 2018 and June 30, 2017 , there was $1.5 million of interest and $0.7 million of interest, respectively, capitalized into construction in progress. For the six months ended June 30, 2018 and June 30, 2017 , there was $2.8 million of interest and $1.2 million of interest, respectively, capitalized into construction in progress. This increase in capitalized interest is related to outstanding costs for the Company's facility expansion project in Buena. During the three months ended June 30, 2018 and June 30, 2017 , there was $0.7 million of payroll costs and $0.2 million of payroll costs, respectively, capitalized into construction in progress. For the six months ended June 30, 2018 and June 30, 2017 , there was $1.1 million of payroll costs and $0.4 million of payroll costs, respectively, capitalized into construction in progress.

Debt

Debt	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Debt	Debt Convertible Notes On December 16, 2014, the Company issued $125.0 million aggregate principal amount of Convertible 3.75% Senior Notes, due 2019 (the “2019 Notes”). On December 22, 2014, the Company announced the closing of the initial purchasers’ exercise in full of their option to purchase an additional $18.75 million aggregate principal amount of 2019 Notes. The 2019 Notes bear interest at a fixed rate of 3.75% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2015, and mature on December 15, 2019, unless earlier repurchased, redeemed or converted. The 2019 Notes are convertible into shares of the Company’s common stock, cash or a combination thereof. On May 20, 2015, the Company received shareholder approval for the increase in the number of shares of common stock authorized and available for issuance upon conversion of the 2019 Notes. On April 27, 2018, the Company entered into separate exchange agreements with certain holders of the 2019 Notes. The agreements gave the holders the right to exchange, in aggregate, $75.1 million of the 2019 Notes for $75.1 million of new Convertible 4.75% Senior Notes due 2023 (the “2023 Notes”). The new 2023 Notes bear a fixed interest rate of 4.75% per year, payable semi-annually with the principal payable in May 2023. At the option of the holders, the 2023 Notes are convertible into shares of the Company’s common stock, cash or a combination thereof. The initial conversion rate is $224.71 per share, subject to certain adjustments, related to either the Company's stock price volatility, or the Company's declaration of a stock dividend, stock distribution, share combination or share split expected dividends or other anti-dilutive activities. In addition, holders will be entitled to receive additional shares of common stock for a potential increase of the conversion rate up to $280.90 per share under a make-whole provision in some circumstances. The Company incurred loan issue costs of $1.6 million upon issuance of the 2023 Notes. In accordance with accounting for convertible debt within the cash conversion guidance of ASC 470-20, we allocated the principal amount of the 2023 Notes between its liability and equity components. The carrying amount of the liability component was determined by measuring the fair value of a similar debt instrument of similar credit quality and maturity that did not have the conversion feature. The carrying amount of the equity component, representing the embedded conversion option, was determined by deducting the fair value of the liability component from the principal amount of the 2023 Notes as a whole. The equity component was recorded to additional paid-in capital and is not remeasured as long as it continues to meet the conditions for equity classification. The excess of the principal amount of the 2023 Notes over the carrying amount of the liability component was recorded as a debt discount of $19 million , and is being amortized to interest expense using the effective interest method through the maturity date. We allocated the total amount of transaction costs incurred to the liability and equity components using the same proportions as the proceeds from the 2023 Notes. Transaction costs attributable to the liability component were recorded as a direct deduction from the liability component of the 2023 Notes, and are being amortized to interest expense using the effective interest method through the maturity date. Transaction costs attributable to the equity component were netted with the equity component of the 2023 Notes in additional paid-in capital. The effective interest rate of the 2023 Notes, inclusive of the debt discount and issuance costs, is 12.10% . The exchange of $75.1 million of the 2019 Notes for the 2023 Notes is considered an extinguishment under ASC 470-50. The 2019 Notes are accounted for under cash conversion guidance ASC 470-20, which requires the Company to allocate the fair value of the consideration transferred upon settlement to the extinguishment of the liability component and the reacquisition of the equity component upon derecognition. In accordance with the aforementioned guidance, the Company recorded $2.5 million of non-cash interest expense as an extinguishment loss related to the 2019 Notes in the Condensed Consolidated Statement of Operations. In addition the Company recorded a $7.6 million reduction of Additional Paid in Capital in connection with the extinguishment of $75.1 million of the 2019 Notes. Term Loan On June 1, 2018, the Company entered into a credit agreement for $25.0 million secured by all Company assets, due June 1, 2021 (“2021 Term Loan”). The 2021 Term Loan has limited financial and non-financial covenants inclusive of a minimum cash carry balance of $5.0 million . The 2019 Notes and 2023 Notes are subordinate to the 2021 Term Loan. The first $15.0 million of loan proceeds was received on June 1, 2018. The remaining loan proceeds of $10.0 million were subject to closing conditions as defined in the agreement and were received on July 16, 2018. The 2021 Term Loan incurred loan issue costs of $0.5 million and a discount of $0.4 million . The discount is due to lender fees paid on the initial drawdown of $15.0 million . The issue costs and discount are recognized as interest expense over the term of the 2021 Term Loan. The 2021 Term Loan bears interest at a rate of LIBOR plus 9% , with a stated floor of 2% . The effective interest, inclusive of the debt discounts and issue costs is 12.78% 13.56% per year. At June 30, 2018 and December 31, 2017, the net carrying value of the debt and the remaining unamortized debt discounts and debt issuance costs were as follows (in thousands): June 30, 2018 December 31, 2017 (Unaudited) (Audited) Face amount of the 2019 Notes (non-current due December 2019) $ 68,660 $ 143,750 Face amount of the 2021 Loan (non-current due June 2021) 15,000 — Face amount of the 2023 Notes (non-current due May 2023) 75,090 — 158,750 143,750 Less unamortized discounts and debt issuance costs 28,871 22,773 Total Carrying Value, Net $ 129,879 $ 120,977 For the six months ended June 30, 2018 and 2017 , the Company recorded the following expenses in relation to the debt (in thousands): Three months ended June 30, Six months ended June 30, 2018 2017 2018 2017 Interest expense of the 2019 Notes (1) $ 878 $ 1,347 $ 2,226 $ 2,695 Interest expense of the 2021 Loan 141 — 141 — Interest expense of the 2023 Notes (1) 634 — 634 — Debt partial extinguishment of 2019 Notes 2,467 — 2,467 — Debt discount amortization of the 2019 Notes (1) 1,571 2,126 3,910 4,183 Debt discount amortization of the 2021 Loan 14 — 14 — Debt discount amortization of the 2023 Notes (1) 498 — 498 — Debt financing amortization of the 2019 Notes (1) 191 232 446 456 Debt financing amortization of the 2021 Loan 17 — 17 — Debt financing amortization of the 2023 Notes (1) 42 — 42 — Interest expense $ 6,453 $ 3,705 $ 10,395 $ 7,334 (1) Included within "Interest and other expense, net" on the Condensed Consolidated Statements of Operations, offset by interest income and capitalized interest, as disclosed Note 6.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The Company acquired the assets of Canadian pharmaceutical company Alveda Pharmaceuticals, Inc., in November 2015. As a result of the acquisition, we recorded goodwill of $0.4 million . We assess the recoverability of the carrying value of goodwill in the fourth quarter of each year, and whenever events occur or circumstances change that would, more likely than not, reduce the fair value of our reporting unit below its carrying value. There have been no events or changes in circumstances that would have reduced the fair value of our reporting unit below its carrying value from December 31, 2017 , through June 30, 2018 . No impairment losses were recognized during the six months ended June 30, 2018 . Changes to the carrying value in goodwill during the six months ended June 30, 2018 and the year ending December 31, 2017 were as follows (in thousands): Goodwill Goodwill balance at December 31, 2016 $ 446 Foreign currency translation 25 Goodwill balance at December 31, 2017 471 Foreign currency translation (26 ) Goodwill balance at June 30, 2018 $ 445 Intangible Assets The following sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of June 30, 2018 and December 31, 2017 (in thousands). June 30, 2018 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 39,294 $ (6,875 ) $ 32,419 12.4 In process research and development ("IPR&D") 17,831 — 17,831 N/A Customer relationships 3,637 (957 ) 2,680 7.6 Total $ 60,762 $ (7,832 ) $ 52,930 December 31, 2017 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 40,380 $ (5,684 ) $ 34,696 12.8 In-process research and development ("IPR&D") 18,311 — 18,311 N/A Customer relationships 3,783 (773 ) 3,010 7.9 Total $ 62,474 $ (6,457 ) $ 56,017 Changes in intangibles during the six months ended June 30, 2018 were as follows (in thousands): Trademarks and Technology IPR&D Customer Relationships Balance at January 1, 2018 $ 34,696 $ 18,311 $ 3,010 Amortization (1,363 ) — (187 ) Loss on impairment (7 ) (15 ) — Foreign currency translation (907 ) (465 ) (143 ) Balance at June 30, 2018 $ 32,419 $ 17,831 $ 2,680 Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of June 30, 2018 over the remainder of 2018 and each of the next five years is estimated to be as follows (in thousands): Amortization Expense * 2018 (remainder of the year) $ 1,550 2019 3,099 2020 3,099 2021 3,099 2022 3,099 2023 3,099 Thereafter 18,054 Total $ 35,099 *IPR&D amounts are assessed for impairment at least annually and will be amortized once products are approved, including the product's respective manufacturing process approvals, and are not included in the table. The useful lives of the Company’s intangibles are as follows: Intangibles Category Amortizable Life Trademarks and Technology 15 Customer Relationships 10

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock Options The Company recognized $0.3 million and $0.6 million of compensation expense related to stock options during the three months ended June 30, 2018 and 2017 , respectively, and $0.8 million and $1.2 million during the six months ended June 30, 2018 and 2017 . The 1999 Director Stock Option Plan, as amended (the “Director Plan”), provides for the grant of stock options to non-employee directors of the Company at an exercise price equal to the fair market value per share on the date of the grant. As of December 31, 2017 , an aggregate of 1,975,000 shares had been approved and authorized for issuance pursuant to the Director Plan with no change as of June 30, 2018 . A total of 2,634,798 options had been granted to non-employee directors through December 31, 2017 , with no change as of June 30, 2018 . A total of 807,782 of those had been forfeited through December 31, 2017 and returned to the option pool for future issuance, with no change as of June 30, 2018 . The options granted under the Director Plan vest in full one year after their respective grant dates and have a maximum term of ten years . As of December 31, 2017 and June 30, 2018 there were 500,000 shares of common stock options outstanding. As of December 31, 2017 , the 147,984 options available were transferred to a plan that has superseded the Director Plan, as discussed further in this section, with no additional options transferred as of June 30, 2018 . The 1999 Stock Incentive Plan, as amended (“1999 Plan”), replaced all previously authorized employee stock option plans, and no additional options may be granted under those previous plans. Under the 1999 Plan, options or stock awards may be granted to all of the Company’s employees, officers, directors, consultants and advisors to purchase a maximum of 3,200,000 shares of common stock. However, pursuant to the terms of the 1999 Plan, no awards may be granted after March 16, 2009. A total of 2,892,500 options, having a maximum term of ten years , have been granted at 100% of the fair market value of the Company’s common stock at the date of grant. Options outstanding under the 1999 Plan were generally exercisable in cumulative increments over four years commencing one year from date of grant. As of June 30, 2018, there are no options outstanding under the 1999 Plan. On June 26, 2009, the Board of Directors adopted, and the Company’s stockholders subsequently approved by written consent, the IGI Laboratories, Inc. 2009 Equity Incentive Plan (the “2009 Plan”). The 2009 Plan became effective on July 29, 2009. The 2009 Plan allows the Company to continue to grant options and restricted stock, as under the 1999 Plan, but also authorizes the Board of Directors to grant a broad range of other equity-based awards, including stock appreciation rights, restricted stock units (“RSUs”) and performance awards. The 2009 Plan has been created, pursuant to and consistent with the Company's current compensation philosophy, to assist the Company in attracting, retaining and rewarding designated employees, directors, consultants and other service providers of the Company and its subsidiaries and affiliates, in a manner that will be cost efficient to the Company from both an economic and financial accounting perspective. On April 12, 2010, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2009 Plan to increase the number of shares of Common Stock available for grant under such plan by adding 2,000,000 shares of Common Stock. The 2009 Plan, as amended on May 29, 2010, authorizes up to 5,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2009 Plan. The maximum number of shares that may be subject to awards made to any individual in any single calendar year under the 2009 Plan is 1,000,000 shares. As of June 30, 2018 , there were 24,376 RSUs outstanding, 1,493,960 shares of stock outstanding, and options to purchase 2,932,846 shares of common stock outstanding. As of December 31, 2017 , there were 99,626 RSUs outstanding, 1,422,020 shares of stock outstanding and options to purchase 3,038,634 shares of common stock outstanding. As of December 31, 2017 , the 249,052 options available were transferred to a plan that has superseded the 2009 Plan, as discussed further in this section. As of June 30, 2018 , an additional 98,098 options available were transferred to the superseded plan. On May 25, 2016, the Board of Directors approved the Company’s 2016 Equity Incentive Plan (the “ 2016 Plan”). On May 21, 2018, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2016 Plan to increase the number of shares of Common Stock available for grant under such plan by adding 2,000,000 shares of Common Stock. The 2016 Plan, as amended, provides for the issuance of awards of up to 4,000,000 shares of the Company’s common stock, plus any shares of common stock that are represented by awards granted under our Director Plan and 2009 Plan that are forfeited, expire or are canceled without delivery of shares of common stock or which result in the forfeiture of shares of common stock back to the Company on or after May 25, 2016, up to 2,500,000 shares. Generally, shares of common stock reserved for awards under the 2016 Plan that lapse or are canceled, will be added back to the share reserve available for future awards. However, shares of common stock tendered in payment for an award or shares of common stock withheld for taxes will not be available again for grant. The 2016 Plan provides that no participant may receive awards for more than 1,000,000 shares of common stock in any fiscal year. As the 2016 Plan supersedes both the Director Plan and the 2009 Plan, any available shares from both are now incorporated into the 2016 Plan. As of June 30, 2018 , there were 174,472 RSUs outstanding, 49,667 shares of common stock outstanding and options to purchase 1,335,529 shares of common stock outstanding under the 2016 Plan. As compared to 2017 , as of December 31, 2017 , there were 89,003 RSUs outstanding, 20,000 shares of common stock outstanding and options to purchase 761,176 shares of common stock outstanding under the 2016 Plan. As of June 30, 2018 and December 31, 2017 , there were a total of 2,935,736 shares of common stock and 1,526,857 shares of common stock available under the 2016 Plan, respectively. As of June 30, 2018 and December 31, 2017 , there were options to purchase 4,768,105 and 4,299,810 shares of common stock outstanding, respectively, collectively in the Director Plan, 2009 Plan, and the 2016 Plan. In the interest of maintaining consistency with the Company's 2016 Equity Incentive Plan, on March 13, 2017, the Company entered into (i) an amendment to the option agreements governing each option grant currently outstanding under the Company's 2009 Equity Incentive Plan, and (ii) an amendment to the RSU, agreements governing each RSU grant currently outstanding under the 2009 Plan. The amendments provide for the automatic vesting upon a change of control of the Company of each option grant and RSU grant, as applicable, outstanding under the 2009 Plan. The amendments had a de minimis value to the holders as of June 30, 2018 , and therefore no additional stock compensation expense was recognized related to the amendments. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. Six months ended June 30, Assumptions 2018 2017 Expected dividends — — Risk-free rate 2.36 % 1.55 % Expected volatility 60.5% - 62.3% 58.0% - 69.7% Expected term (in years) 3.2 - 3.3 years 3.2 - 3.3 years Expected volatility was calculated using the historical volatility of the Company's stock over the expected life of the options. The expected life of the options was estimated based on the Company's historical data. The risk-free interest rate is based on U.S. Treasury yields for securities with terms approximating the terms of the grants. Forfeitures are recognized in the period they occur. The assumptions used in the Black-Scholes options valuation model are highly subjective and can materially affect the resulting valuation. A summary of option activity under the Director Plan, the 2009 Plan and the 2016 Plan as of June 30, 2018 and changes during the period are presented below: Number of Options Weighted Average Exercise Price Outstanding as of January 1, 2018 4,299,810 $ 5.09 Issued 679,785 3.29 Exercised (11,000 ) 1.08 Forfeited (200,490 ) 7.02 Expired — — Outstanding as of June 30, 2018 4,768,105 $ 4.76 Exercisable as of June 30, 2018 3,546,700 $ 4.63 The following tables summarize information regarding options outstanding and exercisable at June 30, 2018 : Outstanding: Range of Exercise Prices Stock Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life $0.55 - $1.50 1,735,000 $ 1.06 3.61 $1.51 - $5.50 873,469 3.18 8.52 $5.51 - $10.67 2,159,636 8.38 7.45 Total 4,768,105 $ 4.76 6.25 Exercisable: Range of Exercise Prices Stock Options Exercisable Weighted Average Exercise Price $0.55 - $1.50 1,735,000 $ 1.06 $1.51 - $5.50 202,166 2.75 $5.51 - $10.67 1,609,534 8.72 Total 3,546,700 $ 4.63 As of June 30, 2018 , the intrinsic value of the options outstanding was $4.5 million and the intrinsic value of the options exercisable was $4.3 million . As of June 30, 2018 , there was $2.0 million of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the Plan. The costs will be recognized through February 2021. Restricted Stock and RSUs The Company periodically grants restricted stock and RSU awards to certain officers and other employees that typically vest one to three years from their grant date. The Company recognized $0.1 million and $ 0.2 million of compensation expense during the three months ended June 30, 2018 and 2017 , respectively, and $0.3 million and $0.5 during the six months ended June 30, 2018 and 2017, respectively, related to restricted stock and RSU awards. Stock compensation expense is recognized over the vesting period of the restricted stock and RSUs. At June 30, 2018 , the Company had approximately $0.8 million of total unrecognized compensation cost related to non-vested restricted stock and RSUs, all of which will be recognized through April 2021. The following table summarizes the number of unvested RSUs and their weighted average exercise price for the six months ended June 30, 2018 . Number of RSUs Weighted Average Exercise Price Non-vested balance at January 1, 2018 188,629 $ 8.27 Changes during the period: Shares granted 122,949 3.36 Shares vested (101,607 ) 9.07 Shares forfeited (11,123 ) 7.21 Non-vested balance at June 30, 2018 198,848 $ 4.88

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company’s income tax expense was $0.02 million and $0.02 million for the three months ended June 30, 2018 and 2017, respectively. For the same two periods, the effective tax rates were 0.2% and 2.6% , respectively. The Company’s income tax expense was $0.04 million and $0.1 million for the six months ended June 30, 2018 and 2017, respectively and the effective tax rates were 0.3% and 589% , respectively. The Company conducts operations in the United States and certain foreign countries. It is the intent of the Company to permanently reinvest any earnings and profits generated by its foreign affiliates. One of its foreign affiliates is subject to tax in Estonia. Estonia has a dual tax regime: 0% tax rate for earnings and profits as they are generated and 14% to 20% tax rates for earnings and profits that are distributed to shareholders. The Company has taken the position that the 14% to 20% tax rates apply only when dividends have been declared and recognized as a liability. Accordingly, the Company has provided no taxes on the current earnings generated by its Estonian affiliate. Income tax expense for the three and six months ended June 30, 2018 and June 30, 2017 , is recognized based on the Company’s estimated annual effective tax rate, which is based on the tax rate expected for the full calendar year applied to the pre-tax income of the interim period adjusted for discrete items. The Company excludes from the calculation of the annual effective tax rate those jurisdictions that are projected to operate at a loss and in which a tax benefit will not be recognized or which operate in a zero tax rate jurisdiction. The Company has assessed the impacts of the changes resulting from the United States Tax Cuts and Jobs Act (U.S. TCJA) and has recognized an income tax benefit and a corresponding receivable of $0.1 million related to the recoverability of Alternative Minimum Tax Credits. Deferred tax assets, liabilities and valuation allowances have been remeasured at the new rate of 21% . Except for the recognition of the Alternative Minimum Tax Credit, there was no income impact from the remeasurement since all U.S. net deferred tax assets are fully reserved by the Company. At present, we do not estimate any material impacts from the repatriation tax. While we have completed our provisional analysis of the income tax effects of the U.S.TCJA, the related tax effects may need to be adjusted, possibly materially, due to further refinement of our calculations, changes in interpretations and assumptions that we have made, additional guidance that may be issued by regulatory bodies, and actions and related accounting policy decision we may take as a result of the new legislation. We will complete our analysis over the one-year measurement period from the enactment of the law as provided for by "Income Tax Accounting Implications of the Tax Cuts and Jobs Act" (SAB 118), and any adjustments during this measurement period will be included in net earnings from continuing operations as an adjustment to income tax expense in the reporting period(s) when such adjustments are determined. The Company evaluates the recoverability of its net deferred tax assets based on its history of operating results, its expectations for the future and expiration dates. Based on the preponderance of the evidence, the Company has concluded that it is more likely than not it will be unable to realize the net deferred tax assets in the immediate future and has established a valuation allowance for all U.S. and foreign net deferred tax assets. At December 31, 2017 , the Company’s U.S. federal net operating loss carryforwards totaled $41.7 million . The Company’s ability to use net operating loss carry forwards is subject to limitation in future periods under certain provisions of Section 382 of the Internal Revenue Code of 1986, as amended, which limit the utilization of net operating losses upon a more than 50% change in ownership of the Company’s stock that is held by 5% or greater stockholders. The Company examined the application of Section 382 with respect to an ownership change that took place during 2010, as well as the limitation on the application of net operating loss carry forwards. The Company believes that operating losses subsequent to the change date in 2010 (aggregating $23.1 million ) are not subject to Section 382 limitations. The Company has estimated that the annual limitation starting in 2010 aggregates from $1.0 million to $2.3 million per year including the effect of amortization of built in gains. The Company’s loss carryforwards may be further limited in the future if additional ownership changes occur. The Company is subject to the provisions of ASC 740-10-25, “ Income Taxes” . ASC 740 prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. On a quarterly basis, the Company undergoes a process to evaluate whether income tax accruals are in accordance with ASC 740 guidance on uncertain tax positions. For federal purposes, post 1998 tax years remain open to examination as a result of net operating loss carryforwards. The Company is currently open to audit by the appropriate state income taxing authorities for tax years 2013 to 2017. The Company has not recorded any liability for uncertain tax positions.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2018
Other Income and Expenses [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses represent various obligations of the Company including certain operating expenses and taxes payable. As of June 30, 2018 and December 31, 2017 , the largest components of accrued expenses were (in thousands): June 30, 2018 December 31, 2017 (Unaudited) (Audited) Capital expenditures $ 2,476 $ 1,947 Payroll 1,483 1,580 Professional fees 1,284 546 Interest expense 763 240 Clinical studies 603 596 Royalties 578 856 Medicaid and Medicare 542 1,487 Inventory and Supplies 460 58 Rebates 332 83 Income Tax 60 58 Other 688 650 $ 9,269 $ 8,101

Legal and U.S. Regulatory Proce

Legal and U.S. Regulatory Proceedings	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Legal and U.S. Regulatory Proceedings	Legal and U.S. Regulatory Proceedings The Company is involved from time to time in claims which arise in the ordinary course of business. In management's opinion, the Company has made adequate provision for potential liabilities, if any, arising from any such matters. However, litigation is inherently unpredictable, and the costs and other effects of pending or future litigation, governmental investigations, legal and administrative cases and proceedings (whether civil or criminal), settlements, judgments and investigations, claims and changes in any such matters, and developments or assertions by or against the Company relating to intellectual property rights and intellectual property licenses, could have a material adverse effect on its business, financial condition and operating results. To date, twelve putative class action antitrust lawsuits have been filed against the Company along with co-defendants, including Taro Pharmaceuticals U.S.A., Inc. and Perrigo New York Inc. One “opt-out” action has additionally been filed against the Company along with thirty-four generic manufacturer co-defendants regarding the pricing of econazole nitrate cream along with twenty-nine additional drug products not manufactured or sold by the Company. All actions have been consolidated by the Judicial Panel on Multidistrict Litigation to the Eastern District of Pennsylvania for pre-trial proceedings as part of the In re Generic Pharmaceuticals Pricing Antitrust Litigation matter, and the class actions have been consolidated into three actions: the direct purchaser, end payer and indirect reseller actions. The class plaintiffs seek to represent nationwide or state classes consisting of persons who directly purchased, indirectly purchased, paid and/or reimbursed patients for the purchase of generic econazole from July 1, 2014 until the time the defendants’ allegedly unlawful conduct ceased or will cease. The opt-out plaintiffs allege a conspiracy by thirty-five generic manufacturers to fix prices for thirty drug products, including econazole nitrate cream, in violation of federal antitrust laws. The opt-out plaintiffs seek treble damages for alleged price overcharges for the thirty drug products identified in the complaint during the alleged period of conspiracy, and also seek injunctive relief against the defendants. All of these cases are in their initial stages and motions to dismiss have been filed with respect to each of the three consolidated class actions. Due to the early stage of these cases, we are unable to form a judgment at this time as to whether an unfavorable outcome is either probable or remote or to provide an estimate of the amount or range of potential loss. We believe these cases are without merit, and we intend to vigorously defend against these claims. On October 20, 2017, a Demand for Arbitration was filed with the American Arbitration Association by Stayma Consulting Services, Inc. (“Stayma”) against the Company regarding the Company’s development and manufacture for Stayma of two generic drug products, one a lotion and one a cream, containing 0.05% of the active pharmaceutical ingredient flurandrenolide. The Company developed the two products and Stayma purchased commercial quantities of each; however, Stayma alleges that the Company breached agreements between the parties by developing an additional and different generic drug product, an ointment, containing flurandrenolide, and failing to meet certain contractual requirements. Stayma seeks monetary damages. Because discovery in this matter is ongoing, the Company is unable to form a judgment at this time as to whether an unfavorable outcome is either probable or remote or to provide an estimate of the amount or range of potential loss. The Company believes this case is without merit, and the Company intends to vigorously defend against these claims. The Company filed a counter-claim against Stayma for its failure to pay several past due invoices of approximately $1.7 million relating to the development and commercial supply of the two subject products. These invoices have been fully reserved.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company was unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 with the SEC by the required filing date due to additional time required to restate the Company’s interim condensed consolidated financial statements for the three and six-months ended June 30, 2018 for the matters disclosed in Note 1. As a result, the Company was not in compliance with the non-financial covenant prescribed by the Term Loan disclosed in Note 7 as of September 30, 2018, which requires timely filing of the Company’s annual and interim consolidated financial statements, and the Company’s ability to offer up to $50.0 million in debt or equity securities through its existing shelf registration statement on file with the SEC was suspended for a period of twelve months. Moreover, due to the lack of compliance with the non-financial covenant prescribed by the Term Loan, the Company reclassified the net carrying value of $24.2 million as current debt in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018. On November 12, 2018, the Company entered into a financing commitment whereby Ares Capital Management (“Ares”) has agreed to loan the Company up to $120.0 million (“Ares Credit Facility”). The Ares Credit Facility will be secured by all of the Company’s asset and will be funded in three tranches: (1) an asset based revolving credit facility of $25.0 million due November 2022 (“2022 Revolver”), (2) a term loan of $80.0 million due February 2023 (“2023 Term Loan”), and (3) a delayed draw term loan of $15.0 million also due in February 2023 (“2023 Delayed Draw Term Loan”). In addition, the Ares Credit Facility will require the Company to comply with certain affirmative non- financial covenants relating to periodic reporting and maintaining compliance with standard rules and regulations customary in the markets where the Company competes, as well as negative financial covenants limiting levels of indebtedness and restricting certain payments, as well as minimum revenue covenants for each twelve-month period ending December 31, 2018, March 31, 2019 and June 30, 2019, minimum consolidated adjusted EBITDA covenants for the twelve-month period ending September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020 and September 30, 2020 and minimum net leverage ratio covenants for the twelve-month period ending December 31, 2020 and ending each fiscal quarter thereafter until maturity. The 2023 Term Loan and 2023 Delayed Draw Term Loan will be subordinate to the 2022 Revolver. The proceeds from both the 2022 Revolver and 2023 Term Loan are anticipated to be funded in the fourth quarter upon execution of the final agreements with Ares, whereas the 2023 Delayed Draw Term Loan will be made available when the Company initiates capital improvements to substantially increase manufacturing capacity in its Buena, New Jersey injectable manufacturing facility, which is currently to begin in fiscal year 2018. The Company intends to use the proceeds from 2023 Term Loan to extinguish its existing $25.0 million 2021 Term Loan, as well as extinguish its remaining outstanding $68.7 million of December 2019 Notes. The 2022 Revolver will bear interest at a rate of LIBOR plus 3.75% , whereas the 2023 Term Loan and 2023 Delayed Draw Term Loan will bear interest at a rate of LIBOR plus 8.75% with a 24-month paid-in-kind interest option available to the Company should it choose to defer cash interest payments in order to provide further liquidity to continue launching new products.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the historical valuation of the derivative liability, sales returns and allowances, allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related valuation allowances, stock based compensation, the assessment for the impairment of long-lived assets (including intangibles, goodwill and property, plant and equipment), property, plant and equipment and legal accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid instruments purchased with the original maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. Cash and cash equivalents include cash on hand and bank demand deposits used in the Company’s cash management program.
Stock Based Compensation	Stock Based Compensation ASC 718-10 defines the fair-value-based method of accounting for stock-based employee compensation plans and transactions used by the Company to account for its issuances of equity instruments to record compensation cost for stock-based employee compensation plans at fair value as well as to acquire goods or services from non-employees. Transactions in which the Company issues stock-based compensation to employees, directors and advisors and for goods or services received from non-employees are accounted for based on the fair value of the equity instruments issued. The Company utilizes pricing models in determining the fair values of options, restricted stock units ("RSU's") and warrants issued as stock-based compensation. These pricing models utilize the market price of the Company’s common stock and the exercise price of the option or warrant, as well as time value and volatility factors underlying the positions. Stock-based compensation expense is recognized over the requisite service period of the award, which usually coincides with the vesting period of the grant.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, trade receivables, notes payable, accounts payable and other accrued liabilities at June 30, 2018 approximate their fair value for all periods presented.
Earnings (Loss) Per Share	Loss Per Share Basic loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Potential dilutive common stock equivalents include shares issuable upon the conversion of the 2019 and 2023 Notes, the exercise of options, and the vesting RSU's.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. The Company's revenue is recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. The Company derives its revenues from three types of transactions: sales of its own pharmaceutical products (Company product sales), sales of manufactured product for its customers (contract manufacturing sales), and research and product development services performed for third parties. Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each. Taxes collected from customers and remitted to government authorities and that are related to the sales of the Company’s products are excluded from revenues. See more detailed information in Note 4. Adoption of ASC Topic 606, "Revenue from Contracts with Customers” In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” The standard, including subsequently issued amendments, replaces most existing revenue recognition guidance in U.S. GAAP. The key focus of the new standard is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performed a comprehensive review of its existing revenue arrangements as of January 1, 2018 following the aforementioned five-step model. Based on the Company's analysis, there were no changes identified that impacted the amount or timing of revenues recognized under the new guidance as compared to the previous guidance. Additionally, the Company's analysis indicated that there were no changes to how costs to obtain and fulfill our customer contracts would be recognized under the new guidance as compared to the previous guidance. The impact of the adoption of this standard on the Company's Condensed Consolidated Balance Sheet, Condensed Consolidated Statement of Operations, and Condensed Consolidated Statement of Cash Flows was not material. The adoption of the new guidance impacted the way the Company analyzes, documents, and discloses revenue recognition under customer contracts beginning on January 1, 2018 and resulted in additional disclosures in the Company's financial statements.
Property, Plant and Equipment	Property, Plant and Equipment Depreciation and amortization of property, plant and equipment is provided for under the straight-line method over the assets’ estimated useful lives as follows: Useful Lives Buildings and Improvements 10 - 40 years Machinery and Equipment 5 - 15 years Computer Hardware and Software 3 - 5 years Furniture Fixtures 5 years Leasehold improvements are amortized over the shorter of estimated useful life or the lease term. Repair and maintenance costs are charged to operations as incurred while major improvements are capitalized. Construction in progress ("CIP") costs are amortized based on the asset class when they are put into service. When assets are retired or disposed, the related cost and accumulated depreciation thereon are removed and any gains or losses are included in operating results.
Concentration of Credit Risk	Concentration of Credit Risk Major customers of the Company are defined as those constituting greater than 10% of our total revenue.
Foreign Currency Translation	Foreign Currency Translation The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation account, which is included in Accumulated Other Comprehensive (Loss) ("AOCI") and reflected as a separate component of equity. For those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Foreign currency exchange gain line item under the Other income (expense), net section of the Condensed Consolidated Statement of Operations.
Debt Issuance Costs	Debt Issuance Costs Expenses related to debt financing activities are capitalized and amortized on an effective interest method, over the term of the loan and are to be netted against the carrying value of the financial liability, as required by ASU 2015-3. This standard aligns the treatment of debt issuance costs and debt discounts in that both reduce the carrying value of the liability. Amortization of debt issuance costs is to be recorded as interest expense on the Condensed Consolidated Statement of Operations.
Adoption of Recent Accounting Pronouncements and Recently Issued Accounting Pronouncements	Adoption of Other Recent Accounting Pronouncements In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): "Restricted Cash (a consensus of the FASB Emerging Issues Task Force)". The update addresses the diversity in the industry with respect to classification and presentation of changes in restricted cash on the statement of cash flows. These amendments require that a statement of cash flows explain the restricted cash change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The amendments in this update were effective for fiscal years beginning after December 15, 2017 for public business entities, including interim periods within those fiscal years. For the Company, the amendments were effective January 1, 2018. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): “Clarifying the Definition of a Business”. The update clarifies the definition of a business, specifically for companies to better evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update were effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those annual periods. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-03, Accounting Changes and Error Corrections (Topic 250) and Investments—Equity Method and Joint Ventures (Topic 323): “Amendments to SEC Paragraphs Pursuant to Staff Announcements at the September 22, 2016 and November 17, 2016 EITF Meetings”. The update shows amendments to two SEC Announcements made late in 2016 regarding four specific standards as follows: ASU 2014-09, Revenue from Contracts with Customers (Topic 606), ASU 2016-02, Leases (Topic 842), ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), and ASU 2014-01, Investments - Equity Method and Joint Ventures (Topic 323). The amendments in this update require changes to the U.S. GAAP Financial Reporting Taxonomy and the changes will be incorporated into the proposed 2018 Taxonomy which are available for public comment and finalized as part of the annual release process. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its consolidated financial statements. In February 2017, the FASB issued ASU 2017-05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): “Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets”. This update addresses guidance for partial sales of nonfinancial assets. It affects (i) an entity that enters into a contract to transfer to a customer a nonfinancial asset, group of nonfinancial assets, or ownership interest in a consolidated subsidiary that is not a business or nonprofit entity, (ii) an entity that historically had transactions within the scope of the real estate-specific derecognition guidance, and (iii) an entity that contributes nonfinancial assets that are not a business or a nonprofit activity to a joint venture or other noncontrolled investee. The amendments were effective at the same time as the amendments in ASU 2014-09. Therefore, for the Company, the amendments were effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Public entities may apply the guidance earlier but only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company does not currently expect to enter into any such nonfinancial asset or ownership interest in its consolidated subsidiaries agreements but will refer to the guidance in ASU 2017-05 should that occur. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): “Scope of Modification Accounting”. This update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments affect any entity that changes the terms or conditions of a share-based payment award. The amendments are effective for fiscal years beginning after December 15, 2017. For the Company, the amendments were effective January 1, 2018. The Company has not made any changes to the terms or conditions of share-based payment awards but will refer to the guidance in ASU 2017-09 should that occur. The Company's adoption of this ASU, effective January 1, 2018, did not have a significant impact on its consolidated financial statements. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): “Recognition and Measurement of Financial Assets and Financial Liabilities”. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. The Company is reviewing all lease agreements inclusive of supplier agreements. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): “Simplifying the Test for Goodwill Impairment”. The update simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. It affects public entities that have goodwill reported in their financial statements and have not elected the private company alternative for the subsequent measurement of goodwill. A public entity that is a U.S. Securities and Exchange Commission ("SEC") filer should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. For the Company, the amendments are effective January 1, 2020. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. In February 2018, the FASB issued ASU 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income,” which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. This guidance is effective for all entities for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. The amendments in ASU 2018-02 should be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The adoption of this guidance is not expected to have a material impact on the Company's Consolidated Financial Statements and related disclosures.

Restatement of Previously Iss_2

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Tables)	6 Months Ended
	Jun. 30, 2018
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three months ended June 30, 2018 Six months ended June 30, 2018 As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Revenues: Revenues, net $ 16,751 $ (502 ) (2), (3) $ 16,249 $ 31,296 $ (502 ) (2), (3) $ 30,794 Costs and Expenses: Cost of revenues 11,728 (263 ) (4) 11,465 21,053 (263 ) (4) 20,790 Selling, general and administrative expenses 5,961 (234 ) (3) 5,727 11,321 (234 ) (3) 11,087 Total costs and expenses 21,656 (497 ) 21,159 39,732 (497 ) 39,235 Operating loss (4,905 ) (5 ) (4,910 ) (8,436 ) (5 ) (8,441 ) Other Income (Expense): Partial extinguishment of Convertible 3.75% Notes (10,069 ) 7,602 (1) (2,467 ) (10,069 ) 7,602 (1) (2,467 ) Loss before income tax expense (20,693 ) 7,597 (13,096 ) (25,471 ) 7,597 (17,874 ) Net loss $ (20,716 ) $ 7,597 $ (13,119 ) $ (25,518 ) $ 7,597 $ (17,921 ) Basic and diluted loss per share $ (0.39 ) $ 0.14 $ (0.25 ) $ (0.48 ) $ 0.14 $ (0.34 ) CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, 2018 June 30, 2018 As Previously Reported Adjustments As Restated Accounts receivable, net $ 16,232 $ (151 ) (2) $ 16,081 Total current assets 49,688 (151 ) 49,537 Property, plant and equipment 83,027 263 (4) 83,290 Total assets $ 186,667 $ 112 $ 186,779 Current liabilities: Accounts payable $ 8,654 $ 117 (2) $ 8,771 Total current liabilities 17,923 117 18,040 Convertible 4.75% Senior Notes, net of debt discount and debt issuance costs (face of $75,090, as of June 30, 2018) 54,963 406 (1) 55,369 Total liabilities 147,544 523 148,067 Additional paid in capital 126,532 (8,008 ) (1) 118,524 Accumulated deficit (85,612 ) 7,597 (78,015 ) Total stockholders’ equity 39,123 (411 ) 38,712 Total liabilities and stockholders' equity $ 186,667 $ 112 $ 186,779 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) Three months ended June 30, 2018 Six months ended June 30, 2018 As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Net loss $ (20,716 ) $ 7,597 (1),(2),(3),(4) $ (13,119 ) $ (25,518 ) $ 7,597 (1),(2),(3),(4) $ (17,921 ) Comprehensive loss $ (20,744 ) $ 7,597 (1),(2),(3),(4) $ (13,147 ) $ (25,850 ) $ 7,597 (1),(2),(3),(4) $ (18,253 ) CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Six months ended June 30, 2018 As Previously Reported Adjustments As Restated Net loss $ (25,518 ) $ 7,597 (1),(2),(3),(4) $ (17,921 ) Additional Paid in Capital 126,532 (8,008 ) (1) 118,524 Total Stockholder's Equity $ 39,123 $ (411 ) (1),(2),(3),(4) $ 38,712 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Six months ended June 30, 2018 As Previously Reported Adjustments As Restated Cash flows from operating activities: Net income (loss) $ (25,518 ) $ 7,597 (1),(2),(3),(4) $ (17,921 ) Stock based compensation 1,113 (10 ) (4) 1,103 Partial extinguishment of Convertible 3.75% Senior Notes 10,069 (7,602 ) (1) 2,467 Changes in operating assets and liabilities: Accounts receivable 1,023 (5,250 ) (2),(5), (a) (4,227 ) Accounts payable and accrued expenses (9,604 ) 5,518 (5), (a) (4,086 ) Net cash provided by operating activities (12,763 ) 253 (12,510 ) Cash flows from investing activities: Capital expenditures (12,270 ) (253 ) (4) (12,523 ) Net cash used in investing activities (12,270 ) (253 ) (12,523 ) Non cash investing and financing transactions: Capitalized stock compensation in capital expenditures 53 10 (4) 63 Condensed Consolidated Statements of Operations Three Months Ended June 30, 2017 Six Months Ended June 30, 2017 As Previously Reported Adjustments As Revised As Previously Reported Adjustments As Revised Revenue, net $ 18,408 $ 1,976 (5) $ 16,432 $ 38,299 $ 4,204 (5) $ 34,095 Cost of revenues 10,371 1,976 (5) 8,395 19,328 4,204 (5) 15,124 Total costs and expenses 20,190 1,976 (5) 18,214 37,114 4,204 (5) 32,910 Condensed Consolidated Balance Sheet Condensed Consolidated Balance Sheet June 30, 2017 December 31, 2017 As Previously Reported Adjustments As Revised As Previously Reported Adjustments As Revised Accounts receivable, net $ 27,272 $ 2,853 (5),(6) $ 24,419 $ 18,143 $ 5,401 (5),(6) $ 12,742 Total current assets 95,009 2,853 (5),(6) 92,156 64,532 5,401 (5),(6) 59,131 Total assets 196,385 2,853 (5),(6) 193,532 189,986 5,401 (5),(6) 184,585 Accrued expenses 12,019 2,853 (5),(6) 9,166 13,502 5,401 (5),(6) 8,101 Total current liabilities 21,728 2,853 (5),(6) 18,875 24,097 5,401 (5),(6) 18,696 Total liabilities 137,977 2,853 (5),(6) 135,124 145,233 5,401 (5),(6) 139,832 Total liabilities and stockholders' equity 196,385 2,853 (5),(6) 193,532 189,986 5,401 (5),(6) 184,585 Condensed Consolidated Statement of Cash Flows Six Months Ended June 30, 2017 As Previously Reported Adjustments As Revised Cash flows from operating activities Accounts receivable $ (5,530 ) $ (1,522 ) (5),(6) $ (4,008 ) Accounts payable and accrued expenses 2,414 1,522 (5),(6) 892 For the three and six months ended June 30, 2018, the Company recorded the following adjustments (in thousands) related to prior periods. The net impact of the adjustments on any prior annual or interim periods financial statements was not significant. There were no adjustments related to prior periods recorded for the three and six months ended June 30, 2017. Three months ended Six months ended June 30, 2018 June 30, 2018 Wholesale fees (Revenue) $ 856 $ 1,218 Medicaid (Revenue) 297 297 Pricing and shipment adjustment (Revenue) (2), (3) (502 ) (502 ) Sales return reserve (Revenue) — (577 ) Inventory adjustments (Cost of revenues) — 95 Capitalization of property, plant and equipment (Cost of revenues) (4) 263 263 Bad debt expense (Selling, general and administrative expenses) (578 ) (578 ) $ 336 $ 216

Nature of the Business and Li_2

Nature of the Business and Liquidity (Tables)	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three months ended June 30, 2018 Six months ended June 30, 2018 As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Revenues: Revenues, net $ 16,751 $ (502 ) (2), (3) $ 16,249 $ 31,296 $ (502 ) (2), (3) $ 30,794 Costs and Expenses: Cost of revenues 11,728 (263 ) (4) 11,465 21,053 (263 ) (4) 20,790 Selling, general and administrative expenses 5,961 (234 ) (3) 5,727 11,321 (234 ) (3) 11,087 Total costs and expenses 21,656 (497 ) 21,159 39,732 (497 ) 39,235 Operating loss (4,905 ) (5 ) (4,910 ) (8,436 ) (5 ) (8,441 ) Other Income (Expense): Partial extinguishment of Convertible 3.75% Notes (10,069 ) 7,602 (1) (2,467 ) (10,069 ) 7,602 (1) (2,467 ) Loss before income tax expense (20,693 ) 7,597 (13,096 ) (25,471 ) 7,597 (17,874 ) Net loss $ (20,716 ) $ 7,597 $ (13,119 ) $ (25,518 ) $ 7,597 $ (17,921 ) Basic and diluted loss per share $ (0.39 ) $ 0.14 $ (0.25 ) $ (0.48 ) $ 0.14 $ (0.34 ) CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, 2018 June 30, 2018 As Previously Reported Adjustments As Restated Accounts receivable, net $ 16,232 $ (151 ) (2) $ 16,081 Total current assets 49,688 (151 ) 49,537 Property, plant and equipment 83,027 263 (4) 83,290 Total assets $ 186,667 $ 112 $ 186,779 Current liabilities: Accounts payable $ 8,654 $ 117 (2) $ 8,771 Total current liabilities 17,923 117 18,040 Convertible 4.75% Senior Notes, net of debt discount and debt issuance costs (face of $75,090, as of June 30, 2018) 54,963 406 (1) 55,369 Total liabilities 147,544 523 148,067 Additional paid in capital 126,532 (8,008 ) (1) 118,524 Accumulated deficit (85,612 ) 7,597 (78,015 ) Total stockholders’ equity 39,123 (411 ) 38,712 Total liabilities and stockholders' equity $ 186,667 $ 112 $ 186,779 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) Three months ended June 30, 2018 Six months ended June 30, 2018 As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Net loss $ (20,716 ) $ 7,597 (1),(2),(3),(4) $ (13,119 ) $ (25,518 ) $ 7,597 (1),(2),(3),(4) $ (17,921 ) Comprehensive loss $ (20,744 ) $ 7,597 (1),(2),(3),(4) $ (13,147 ) $ (25,850 ) $ 7,597 (1),(2),(3),(4) $ (18,253 ) CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Six months ended June 30, 2018 As Previously Reported Adjustments As Restated Net loss $ (25,518 ) $ 7,597 (1),(2),(3),(4) $ (17,921 ) Additional Paid in Capital 126,532 (8,008 ) (1) 118,524 Total Stockholder's Equity $ 39,123 $ (411 ) (1),(2),(3),(4) $ 38,712 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Six months ended June 30, 2018 As Previously Reported Adjustments As Restated Cash flows from operating activities: Net income (loss) $ (25,518 ) $ 7,597 (1),(2),(3),(4) $ (17,921 ) Stock based compensation 1,113 (10 ) (4) 1,103 Partial extinguishment of Convertible 3.75% Senior Notes 10,069 (7,602 ) (1) 2,467 Changes in operating assets and liabilities: Accounts receivable 1,023 (5,250 ) (2),(5), (a) (4,227 ) Accounts payable and accrued expenses (9,604 ) 5,518 (5), (a) (4,086 ) Net cash provided by operating activities (12,763 ) 253 (12,510 ) Cash flows from investing activities: Capital expenditures (12,270 ) (253 ) (4) (12,523 ) Net cash used in investing activities (12,270 ) (253 ) (12,523 ) Non cash investing and financing transactions: Capitalized stock compensation in capital expenditures 53 10 (4) 63 Condensed Consolidated Statements of Operations Three Months Ended June 30, 2017 Six Months Ended June 30, 2017 As Previously Reported Adjustments As Revised As Previously Reported Adjustments As Revised Revenue, net $ 18,408 $ 1,976 (5) $ 16,432 $ 38,299 $ 4,204 (5) $ 34,095 Cost of revenues 10,371 1,976 (5) 8,395 19,328 4,204 (5) 15,124 Total costs and expenses 20,190 1,976 (5) 18,214 37,114 4,204 (5) 32,910 Condensed Consolidated Balance Sheet Condensed Consolidated Balance Sheet June 30, 2017 December 31, 2017 As Previously Reported Adjustments As Revised As Previously Reported Adjustments As Revised Accounts receivable, net $ 27,272 $ 2,853 (5),(6) $ 24,419 $ 18,143 $ 5,401 (5),(6) $ 12,742 Total current assets 95,009 2,853 (5),(6) 92,156 64,532 5,401 (5),(6) 59,131 Total assets 196,385 2,853 (5),(6) 193,532 189,986 5,401 (5),(6) 184,585 Accrued expenses 12,019 2,853 (5),(6) 9,166 13,502 5,401 (5),(6) 8,101 Total current liabilities 21,728 2,853 (5),(6) 18,875 24,097 5,401 (5),(6) 18,696 Total liabilities 137,977 2,853 (5),(6) 135,124 145,233 5,401 (5),(6) 139,832 Total liabilities and stockholders' equity 196,385 2,853 (5),(6) 193,532 189,986 5,401 (5),(6) 184,585 Condensed Consolidated Statement of Cash Flows Six Months Ended June 30, 2017 As Previously Reported Adjustments As Revised Cash flows from operating activities Accounts receivable $ (5,530 ) $ (1,522 ) (5),(6) $ (4,008 ) Accounts payable and accrued expenses 2,414 1,522 (5),(6) 892 For the three and six months ended June 30, 2018, the Company recorded the following adjustments (in thousands) related to prior periods. The net impact of the adjustments on any prior annual or interim periods financial statements was not significant. There were no adjustments related to prior periods recorded for the three and six months ended June 30, 2017. Three months ended Six months ended June 30, 2018 June 30, 2018 Wholesale fees (Revenue) $ 856 $ 1,218 Medicaid (Revenue) 297 297 Pricing and shipment adjustment (Revenue) (2), (3) (502 ) (502 ) Sales return reserve (Revenue) — (577 ) Inventory adjustments (Cost of revenues) — 95 Capitalization of property, plant and equipment (Cost of revenues) (4) 263 263 Bad debt expense (Selling, general and administrative expenses) (578 ) (578 ) $ 336 $ 216

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Restrictions on Cash and Cash Equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the Consolidated Balance Sheet to the total amounts in the Consolidated Statement of Cash Flows as follows (in thousands): June 30, 2018 December 31, 2017 June 30, 2017 December 31, 2016 Cash and cash equivalents $ 13,675 $ 26,692 $ 50,216 $ 66,006 Restricted cash in other assets 472 473 475 475 Cash, cash equivalents and restricted cash in the statement of cash flows $ 14,147 $ 27,165 $ 50,691 $ 66,481
Schedule of Earnings Per Share, Basic and Diluted	For the three and six months ended June 30, 2018 , the potential dilutive common stock equivalents have been excluded from the computation of diluted loss per share, as their effect would have been anti-dilutive. (in thousands except shares and per share data) Three months ended June 30, Six months ended June 30, 2018 (Restated) 2017 2018 (Restated) 2017 Basic loss per share computation: Net loss - basic and diluted $ (13,119 ) $ (919 ) $ (17,921 ) $ (88 ) Weighted average common shares - basic and diluted 53,510,712 53,304,407 53,484,756 53,250,109 Basic and diluted loss per share $ (0.25 ) $ (0.02 ) $ (0.34 ) $ 0.00
Schedule Of Property, Plant and Equipment Useful Lives	Depreciation and amortization of property, plant and equipment is provided for under the straight-line method over the assets’ estimated useful lives as follows: Useful Lives Buildings and Improvements 10 - 40 years Machinery and Equipment 5 - 15 years Computer Hardware and Software 3 - 5 years Furniture Fixtures 5 years The useful lives of the Company’s intangibles are as follows: Intangibles Category Amortizable Life Trademarks and Technology 15 Customer Relationships 10

Revenues, Recognition and All_2

Revenues, Recognition and Allowances (Tables)	6 Months Ended
	Jun. 30, 2018
Revenue from Contract with Customer [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles
Disaggregation of Revenues	Net Sales (in thousands) for the three and six months ended June 30, 2018 and 2017 were as follows (prior-period amounts are not adjusted under the modified-retrospective method of adoption): Three months ended June 30, Six months ended June 30, 2018 2017 2018 2017 Company product sales $ 14,677 $ 13,912 $ 27,913 $ 28,120 Contract manufacturing sales 1,450 2,407 2,748 5,824 Research and development services and other income 122 113 $ 133 $ 151 Revenue, net $ 16,249 $ 16,432 $ 30,794 $ 34,095 Disaggregated information for the Company product sales revenue has been recognized in the accompanying unaudited interim Condensed Consolidated Statements of Operations is presented below according to contract type (in thousands): Three months ended June 30, Six months ended June 30, Company Product Sales 2018 2017 2018 2017 Topical $ 7,888 $ 8,558 $ 15,795 $ 16,153 Injectables 6,789 5,354 12,118 11,967 Total $ 14,677 $ 13,912 $ 27,913 $ 28,120
Schedule of Accounts, Notes, Loans and Financing Receivable	The Company's adjustments for the deductions to gross product sales are as follows (in thousands): Three months ended June 30, Six months ended June 30, 2018 2017 2018 2017 Gross product sales $ 48,142 $ 66,744 $ 84,690 $ 121,044 Deduction to gross product sales: Chargebacks and billbacks 21,449 44,090 38,364 74,105 Wholesaler fees for service 477 1,976 1,112 4,204 Sales discounts and other allowances 11,539 6,766 17,301 14,615 Total reduction to gross product sales $ 33,465 $ 52,832 $ 56,777 $ 92,924 Company product sales, net $ 14,677 $ 13,912 $ 27,913 $ 28,120

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories are valued at the lower of cost or net realizable value, using the first-in-first-out method and consist of the following (in thousands): June 30, 2018 December 31, 2017 (Unaudited) (Audited) Raw materials $ 10,655 $ 8,231 Work in progress 944 616 Finished goods 8,434 8,532 Inventories reserve (2,458 ) (1,304 ) Inventories, net $ 17,575 $ 16,075

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment consists of the following (in thousands): June 30, 2018 December 31, 2017 (Unaudited) (Audited) Land $ 257 $ 257 Building and improvements 17,474 8,613 Machinery and equipment 9,674 9,142 Computer hardware and software 4,059 3,244 Furniture and fixtures 553 449 Construction in progress 60,531 55,017 92,548 76,722 Less accumulated depreciation and amortization (9,258 ) (8,367 ) Property, plant and equipment, net $ 83,290 $ 68,355

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Convertible Debt	At June 30, 2018 and December 31, 2017, the net carrying value of the debt and the remaining unamortized debt discounts and debt issuance costs were as follows (in thousands): June 30, 2018 December 31, 2017 (Unaudited) (Audited) Face amount of the 2019 Notes (non-current due December 2019) $ 68,660 $ 143,750 Face amount of the 2021 Loan (non-current due June 2021) 15,000 — Face amount of the 2023 Notes (non-current due May 2023) 75,090 — 158,750 143,750 Less unamortized discounts and debt issuance costs 28,871 22,773 Total Carrying Value, Net $ 129,879 $ 120,977
Schedule of Debt Expense	For the six months ended June 30, 2018 and 2017 , the Company recorded the following expenses in relation to the debt (in thousands): Three months ended June 30, Six months ended June 30, 2018 2017 2018 2017 Interest expense of the 2019 Notes (1) $ 878 $ 1,347 $ 2,226 $ 2,695 Interest expense of the 2021 Loan 141 — 141 — Interest expense of the 2023 Notes (1) 634 — 634 — Debt partial extinguishment of 2019 Notes 2,467 — 2,467 — Debt discount amortization of the 2019 Notes (1) 1,571 2,126 3,910 4,183 Debt discount amortization of the 2021 Loan 14 — 14 — Debt discount amortization of the 2023 Notes (1) 498 — 498 — Debt financing amortization of the 2019 Notes (1) 191 232 446 456 Debt financing amortization of the 2021 Loan 17 — 17 — Debt financing amortization of the 2023 Notes (1) 42 — 42 — Interest expense $ 6,453 $ 3,705 $ 10,395 $ 7,334 (1) Included within "Interest and other expense, net" on the Condensed Consolidated Statements of Operations, offset by interest income and capitalized interest, as disclosed Note 6.

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes to the carrying value in goodwill during the six months ended June 30, 2018 and the year ending December 31, 2017 were as follows (in thousands): Goodwill Goodwill balance at December 31, 2016 $ 446 Foreign currency translation 25 Goodwill balance at December 31, 2017 471 Foreign currency translation (26 ) Goodwill balance at June 30, 2018 $ 445 I
Schedule of Finite and Indefinite Lived Intangible Assets	The following sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of June 30, 2018 and December 31, 2017 (in thousands). June 30, 2018 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 39,294 $ (6,875 ) $ 32,419 12.4 In process research and development ("IPR&D") 17,831 — 17,831 N/A Customer relationships 3,637 (957 ) 2,680 7.6 Total $ 60,762 $ (7,832 ) $ 52,930 December 31, 2017 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 40,380 $ (5,684 ) $ 34,696 12.8 In-process research and development ("IPR&D") 18,311 — 18,311 N/A Customer relationships 3,783 (773 ) 3,010 7.9 Total $ 62,474 $ (6,457 ) $ 56,017
Schedule of Changes in Intangible Assets Other Than Goodwill	Changes in intangibles during the six months ended June 30, 2018 were as follows (in thousands): Trademarks and Technology IPR&D Customer Relationships Balance at January 1, 2018 $ 34,696 $ 18,311 $ 3,010 Amortization (1,363 ) — (187 ) Loss on impairment (7 ) (15 ) — Foreign currency translation (907 ) (465 ) (143 ) Balance at June 30, 2018 $ 32,419 $ 17,831 $ 2,680
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense on product rights and other related intangibles as of June 30, 2018 over the remainder of 2018 and each of the next five years is estimated to be as follows (in thousands): Amortization Expense * 2018 (remainder of the year) $ 1,550 2019 3,099 2020 3,099 2021 3,099 2022 3,099 2023 3,099 Thereafter 18,054 Total $ 35,099 *IPR&D amounts are assessed for impairment at least annually and will be amortized once products are approved, including the product's respective manufacturing process approvals, and are not included in the table.
Schedule Of Property, Plant and Equipment Useful Lives	Depreciation and amortization of property, plant and equipment is provided for under the straight-line method over the assets’ estimated useful lives as follows: Useful Lives Buildings and Improvements 10 - 40 years Machinery and Equipment 5 - 15 years Computer Hardware and Software 3 - 5 years Furniture Fixtures 5 years The useful lives of the Company’s intangibles are as follows: Intangibles Category Amortizable Life Trademarks and Technology 15 Customer Relationships 10

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Valuation Assumptions	The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. Six months ended June 30, Assumptions 2018 2017 Expected dividends — — Risk-free rate 2.36 % 1.55 % Expected volatility 60.5% - 62.3% 58.0% - 69.7% Expected term (in years) 3.2 - 3.3 years 3.2 - 3.3 years
Schedule of Stock Option Activity	A summary of option activity under the Director Plan, the 2009 Plan and the 2016 Plan as of June 30, 2018 and changes during the period are presented below: Number of Options Weighted Average Exercise Price Outstanding as of January 1, 2018 4,299,810 $ 5.09 Issued 679,785 3.29 Exercised (11,000 ) 1.08 Forfeited (200,490 ) 7.02 Expired — — Outstanding as of June 30, 2018 4,768,105 $ 4.76 Exercisable as of June 30, 2018 3,546,700 $ 4.63
Schedule of Stock Options Outstanding and Exercisable	The following tables summarize information regarding options outstanding and exercisable at June 30, 2018 : Outstanding: Range of Exercise Prices Stock Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life $0.55 - $1.50 1,735,000 $ 1.06 3.61 $1.51 - $5.50 873,469 3.18 8.52 $5.51 - $10.67 2,159,636 8.38 7.45 Total 4,768,105 $ 4.76 6.25 Exercisable: Range of Exercise Prices Stock Options Exercisable Weighted Average Exercise Price $0.55 - $1.50 1,735,000 $ 1.06 $1.51 - $5.50 202,166 2.75 $5.51 - $10.67 1,609,534 8.72 Total 3,546,700 $ 4.63
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes the number of unvested RSUs and their weighted average exercise price for the six months ended June 30, 2018 . Number of RSUs Weighted Average Exercise Price Non-vested balance at January 1, 2018 188,629 $ 8.27 Changes during the period: Shares granted 122,949 3.36 Shares vested (101,607 ) 9.07 Shares forfeited (11,123 ) 7.21 Non-vested balance at June 30, 2018 198,848 $ 4.88

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2018
Other Income and Expenses [Abstract]
Schedule of Accrued Expenses	As of June 30, 2018 and December 31, 2017 , the largest components of accrued expenses were (in thousands): June 30, 2018 December 31, 2017 (Unaudited) (Audited) Capital expenditures $ 2,476 $ 1,947 Payroll 1,483 1,580 Professional fees 1,284 546 Interest expense 763 240 Clinical studies 603 596 Royalties 578 856 Medicaid and Medicare 542 1,487 Inventory and Supplies 460 58 Rebates 332 83 Income Tax 60 58 Other 688 650 $ 9,269 $ 8,101

Restatement of Previously Iss_3

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Debt partial extinguishment		$ 2,467	$ 0	$ 2,467	$ 0
Increase (decrease) to non-cash interest expense		(7,600)		(7,600)
Adjustments to additional paid in capital				8,000
Allowance for uncollectible accounts, pricing and shipment error				300
Increase (decrease) in revenue, error		(300)		(300)
Increase (decrease) in accounts receivable, error		(400)		(400)
Increase (decrease) in accounts payable, pricing and shipment error		100		100
Allowance for uncollectible accounts, revenues net error				200
Increase (decrease) in selling, general and administrative expense		(200)		(200)
Property, plant and equipment, net, error		300		300
Increase (decrease) in property, plant and equipment, net, cost of revenue error		$ (300)		$ 300
Reduction of revenue on wholesale fees			2,000		4,200
Reduction of accounts receivable on wholesale fees			5,400		5,400	$ 7,000
Increase (decrease) to accrued expenses, wholesale fees			(5,400)		(5,400)	(7,000)
Increase (decrease) in accounts receivable, error			2,500		2,500	1,600
Increase (decrease) in accrued expenses, error			$ 2,500		$ 2,500	$ 1,600
Convertible Note 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stated interest rate		3.75%		3.75%		3.75%
Debt, transfer	$ 75,100
Debt partial extinguishment	75,100
Non-cash interest expense	$ 10,100	$ 2,500
Convertible Note 2023
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stated interest rate		4.75%		4.75%		4.75%
Unamortized discounts and debt issuance costs		$ 400		$ 400

Restatement of Previously Iss_4

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 1) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue, net	$ 16,249	$ 16,432	$ 30,794	$ 34,095
Cost of revenues	11,465	8,395	20,790	15,124
Selling, general and administrative expenses	5,727	4,706	11,087	9,005
Total costs and expenses	21,159	18,214	39,235	32,910
Operating income (loss)	(4,910)	(1,782)	(8,441)	1,185
Partial extinguishment of Convertible 3.75% Senior Notes	(2,467)	0	(2,467)	0
(Loss) income before income tax expense	(13,096)	(896)	(17,874)	18
Net loss	$ (13,119)	$ (919)	$ (17,921)	$ (88)
Basic and diluted loss per share (in dollars per share)	$ (0.25)	$ (0.02)	$ (0.34)	$ 0
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue, net	$ 16,751		$ 31,296
Cost of revenues	11,728	$ 10,371	21,053	$ 19,328
Selling, general and administrative expenses	5,961		11,321
Total costs and expenses	21,656	20,190	39,732	37,114
Operating income (loss)	(4,905)		(8,436)
Partial extinguishment of Convertible 3.75% Senior Notes	(10,069)		(10,069)
(Loss) income before income tax expense	(20,693)		(25,471)
Net loss	$ (20,716)		$ (25,518)
Basic and diluted loss per share (in dollars per share)	$ (0.39)		$ (0.48)
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue, net	$ (502)		$ (502)
Cost of revenues	(263)	1,976	(263)	4,204
Selling, general and administrative expenses	(234)		(234)
Total costs and expenses	(497)	$ 1,976	(497)	$ 4,204
Operating income (loss)	(5)		(5)
Partial extinguishment of Convertible 3.75% Senior Notes	7,602		7,602
(Loss) income before income tax expense	7,597		7,597
Net loss	$ 7,597		$ 7,597
Basic and diluted loss per share (in dollars per share)	$ 0.14		$ 0.14

Restatement of Previously Iss_5

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 2) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net	$ 16,081	$ 12,742
Total current assets	49,537	59,131	$ 92,156
Property, plant and equipment, net	83,290	68,355
Total assets	186,779	184,585	193,532
Accounts payable	8,771	10,595
Total current liabilities	18,040	18,696	18,875
Convertible 4.75% Senior Notes, net of debt discount and debt issuance costs (face of $75,090, as of June 30, 2018)	55,369	0
Total liabilities	148,067	139,832	135,124
Additional paid-in capital	118,524	106,312
Accumulated deficit	(78,015)	(60,094)
Total stockholders’ equity	38,712	44,753
Total liabilities and stockholders' equity	186,779	184,585	193,532
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net	16,232
Total current assets	49,688	64,532	95,009
Property, plant and equipment, net	83,027
Total assets	186,667	189,986	196,385
Accounts payable	8,654
Total current liabilities	17,923	24,097	21,728
Convertible 4.75% Senior Notes, net of debt discount and debt issuance costs (face of $75,090, as of June 30, 2018)	54,963
Total liabilities	147,544	145,233	137,977
Additional paid-in capital	126,532
Accumulated deficit	(85,612)
Total stockholders’ equity	39,123
Total liabilities and stockholders' equity	186,667	189,986	196,385
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net	(151)
Total current assets	(151)	5,401	2,853
Property, plant and equipment, net	263
Total assets	112	5,401	2,853
Accounts payable	117
Total current liabilities	117	5,401	2,853
Convertible 4.75% Senior Notes, net of debt discount and debt issuance costs (face of $75,090, as of June 30, 2018)	406
Total liabilities	523	5,401	2,853
Additional paid-in capital	(8,008)
Accumulated deficit	7,597
Total stockholders’ equity	(411)
Total liabilities and stockholders' equity	$ 112	$ 5,401	$ 2,853

Restatement of Previously Iss_6

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 3) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ (13,119)	$ (919)	$ (17,921)	$ (88)
Comprehensive loss	(13,147)	$ (1,082)	(18,253)	$ (333)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(20,716)		(25,518)
Comprehensive loss	(20,744)		(25,850)
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	7,597		7,597
Comprehensive loss	$ 7,597		$ 7,597

Restatement of Previously Iss_7

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 4) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ (13,119)	$ (919)	$ (17,921)	$ (88)
Additional paid-in capital	118,524		118,524		$ 106,312
Total stockholders’ equity	38,712		38,712		$ 44,753
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(20,716)		(25,518)
Additional paid-in capital	126,532		126,532
Total stockholders’ equity	39,123		39,123
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	7,597		7,597
Additional paid-in capital	(8,008)		(8,008)
Total stockholders’ equity	$ (411)		$ (411)

Restatement of Previously Iss_8

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 5) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	$ (13,119)	$ (919)	$ (17,921)	$ (88)
Stock based compensation			1,103	1,739
Partial extinguishment of Convertible 3.75% Senior Notes	2,467	$ 0	2,467	0
Accounts receivable			(4,227)	(4,008)
Accounts payable and accrued expenses			(4,086)	892
Net cash used in operating activities			(12,510)	(1,307)
Capital expenditures			(12,523)	(15,286)
Net cash used in investing activities			(12,523)	(15,286)
Capitalized stock compensation in capital expenditures			63	66
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	(20,716)		(25,518)
Stock based compensation			1,113
Partial extinguishment of Convertible 3.75% Senior Notes	10,069		10,069
Accounts receivable			1,023	(5,530)
Accounts payable and accrued expenses			(9,604)	2,414
Net cash used in operating activities			(12,763)
Capital expenditures			(12,270)
Net cash used in investing activities			(12,270)
Capitalized stock compensation in capital expenditures			53
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net loss	7,597		7,597
Stock based compensation			(10)
Partial extinguishment of Convertible 3.75% Senior Notes	$ (7,602)		(7,602)
Accounts receivable			(5,250)	(1,522)
Accounts payable and accrued expenses			5,518	$ 1,522
Net cash used in operating activities			253
Capital expenditures			(253)
Net cash used in investing activities			(253)
Capitalized stock compensation in capital expenditures			$ 10

Restatement of Previously Iss_9

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 6) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Convertible Note 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stated interest rate	3.75%	3.75%
Face amount of the Notes	$ 68,660,000	$ 143,750,000
Convertible Note 2023
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Stated interest rate	4.75%	4.75%
Face amount of the Notes	$ 75,090,000

Restatement of Previously Is_10

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 7) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues, net		$ 16,432		$ 34,095
Cost of revenues	$ 11,465	8,395	$ 20,790	15,124
Total costs and expenses	21,159	18,214	39,235	32,910
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues, net		18,408		38,299
Cost of revenues	11,728	10,371	21,053	19,328
Total costs and expenses	21,656	20,190	39,732	37,114
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues, net		1,976		4,204
Cost of revenues	(263)	1,976	(263)	4,204
Total costs and expenses	$ (497)	$ 1,976	$ (497)	$ 4,204

Restatement of Previously Is_11

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 8) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net		$ 12,742	$ 24,419
Total current assets	$ 49,537	59,131	92,156
Total assets	186,779	184,585	193,532
Accrued expenses	9,269	8,101	9,166
Total current liabilities	18,040	18,696	18,875
Total liabilities	148,067	139,832	135,124
Total liabilities and stockholders' equity	186,779	184,585	193,532
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net		18,143	27,272
Total current assets	49,688	64,532	95,009
Total assets	186,667	189,986	196,385
Accrued expenses		13,502	12,019
Total current liabilities	17,923	24,097	21,728
Total liabilities	147,544	145,233	137,977
Total liabilities and stockholders' equity	186,667	189,986	196,385
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable, net		5,401	2,853
Total current assets	(151)	5,401	2,853
Total assets	112	5,401	2,853
Accrued expenses		5,401	2,853
Total current liabilities	117	5,401	2,853
Total liabilities	523	5,401	2,853
Total liabilities and stockholders' equity	$ 112	$ 5,401	$ 2,853

Restatement of Previously Is_12

Restatement of Previously Issued Unaudited Interim Condensed Consolidated Financial Statements (Details 9) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable	$ (4,227)	$ (4,008)
Accounts payable and accrued expenses	(4,086)	892
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable	1,023	(5,530)
Accounts payable and accrued expenses	(9,604)	2,414
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable	(5,250)	(1,522)
Accounts payable and accrued expenses	$ 5,518	$ 1,522

Nature of the Business and Li_3

Nature of the Business and Liquidity (Details)	Jul. 16, 2018USD ($)	Jun. 01, 2018USD ($)	May 04, 2018USD ($)	Apr. 27, 2018USD ($)	Apr. 30, 2018USD ($)	Jun. 30, 2018USD ($)productsegment	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)productsegment	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 16, 2014
Summary of Significant Accounting Policies Details [Line Items]
Segments | segment						1		1
Cash and cash equivalents						$ 13,675,000		$ 13,675,000		$ 26,692,000
Investments								12,500,000
Accumulated deficit						(78,015,000)		(78,015,000)		$ (60,094,000)
Net loss						$ (13,119,000)	$ (919,000)	(17,921,000)	$ (88,000)
Net decrease in cash, cash equivalents and restricted cash								$ 12,478,000	$ 16,326,000
Shelf offering			$ 50,000,000
United States
Summary of Significant Accounting Policies Details [Line Items]
Generic products marketed | product						28
Branded generic products marketed | product						4
Number of products, launched | product								5
Minimum | Canada
Summary of Significant Accounting Policies Details [Line Items]
Generic and branded products marketed | product						30
Convertible Note 2019
Summary of Significant Accounting Policies Details [Line Items]
Stated interest rate						3.75%		3.75%		3.75%
Debt, transfer					$ 75,100,000
Face amount of the Notes						$ 68,660,000		$ 68,660,000		$ 143,750,000
Convertible Note 2023
Summary of Significant Accounting Policies Details [Line Items]
Stated interest rate						4.75%		4.75%		4.75%
Face amount of the Notes						$ 75,090,000		$ 75,090,000
Term Loan 2021
Summary of Significant Accounting Policies Details [Line Items]
Face amount of the Notes		$ 25,000,000				$ 15,000,000		$ 15,000,000
Proceeds from lines of credit		$ 15,000,000
Subsequent Event | Term Loan 2021
Summary of Significant Accounting Policies Details [Line Items]
Proceeds from lines of credit	$ 10,000,000
Convertible Notes Payable | Convertible Note 2019
Summary of Significant Accounting Policies Details [Line Items]
Stated interest rate						3.75%		3.75%			3.75%
Debt, transfer				$ 75,100,000				$ 75,100,000
Convertible Notes Payable | Convertible Note 2023
Summary of Significant Accounting Policies Details [Line Items]
Stated interest rate				4.75%		4.75%		4.75%
Debt, transfer				$ 75,100,000				$ 75,100,000

Nature of the Business and Li_4

Nature of the Business and Liquidity Nature of the Business and Liquidity (Details 1) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prior period reclassification adjustment	$ 336	$ 216
Wholesale fees (Revenue)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prior period reclassification adjustment	856	1,218
Medicaid (Revenue)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prior period reclassification adjustment	297	297
Pricing and shipment adjustment (Revenue)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prior period reclassification adjustment	(502)	(502)
Sales return reserve (Revenue)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prior period reclassification adjustment	0	(577)
Inventory adjustments (Cost of revenues)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prior period reclassification adjustment	0	95
Capitalization of property, plant and equipment (Cost of revenues)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prior period reclassification adjustment	263	263
Bad debt expense (SG&A)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prior period reclassification adjustment	$ (578)	$ (578)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Cash and cash equivalents	$ 13,675	$ 26,692	$ 50,216	$ 66,006
Restricted cash in other assets	472	473	475	475
Cash, cash equivalents and restricted cash in the statement of cash flows	$ 14,147	$ 27,165	$ 50,691	$ 66,481

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Summary of Significant Accounting Policies Details [Line Items]
Product sales, net	$ 14,677	$ 13,912	$ 27,913	$ 28,120
Assets	186,779	193,532	186,779	193,532	$ 184,585
Domestic
Summary of Significant Accounting Policies Details [Line Items]
Product sales, net	11,400	13,000	21,600	27,800
Assets	125,900	124,800	125,900	124,800
Foreign
Summary of Significant Accounting Policies Details [Line Items]
Product sales, net	4,900	3,400	9,200	6,300
Assets	$ 60,900	$ 68,700	$ 60,900	$ 68,700
Sales Revenue | Customer concentration risk | Two Customers
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk	49.00%		48.00%
Sales Revenue | Customer concentration risk | Three Customers
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk		50.00%		52.00%
Sales Revenue | Customer concentration risk | Customer One
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk	35.00%	26.00%	35.00%	26.00%
Sales Revenue | Customer concentration risk | Customer Two
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk	14.00%	10.00%	13.00%	13.00%
Sales Revenue | Customer concentration risk | Customer Three
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk		14.00%		13.00%
Accounts Receivable
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk			49.00%	67.00%
Convertible Notes Payable
Summary of Significant Accounting Policies Details [Line Items]
Net carrying value of notes	$ 115,700		$ 115,700
Face value of notes	143,750		143,750
Term Loan 2021 | Convertible Notes Payable
Summary of Significant Accounting Policies Details [Line Items]
Net carrying value of notes	14,200		14,200
Face value of notes	$ 15,000		$ 15,000
London Interbank Offered Rate (LIBOR) | Term Loan 2021 | Convertible Notes Payable
Summary of Significant Accounting Policies Details [Line Items]
Basis spread on variable rate	9.00%		9.00%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 1) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Basic loss per share computation:
Net loss	$ (13,119)	$ (919)	$ (17,921)	$ (88)
Weighted average common shares - basic and diluted	53,510,712	53,304,407	53,484,756	53,250,109
Basic and diluted loss per share (in dollars per share)	$ (0.25)	$ (0.02)	$ (0.34)	$ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details 2)	6 Months Ended
	Jun. 30, 2018
Buildings and Improvements | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	10 years
Buildings and Improvements | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	40 years
Machinery and Equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	5 years
Machinery and Equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	15 years
Computer hardware and software | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	3 years
Computer hardware and software | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	5 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life	5 years

Revenues, Recognition and All_3

Revenues, Recognition and Allowances (Details Textual) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018USD ($)transaction_typesegment	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)transaction_type	Jun. 30, 2018USD ($)transaction_type	Jun. 30, 2018USD ($)drugtransaction_type	Jun. 30, 2018USD ($)transaction_typeproduct	Jun. 30, 2018USD ($)transaction_typesegment	Jun. 30, 2018USD ($)transaction_type	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Disaggregation of Revenue [Line Items]
Types of transactions | transaction_type	3		3	3	3	3	3	3
Segments | segment	1						1
Company product sales, net	$ 14,677	$ 13,912						$ 27,913	$ 28,120
Accounts receivable		24,419							24,419	$ 12,742
Increase (decrease) to medicaid reserve								(800)
Accounts receivable, terms of customer credit			100 days
Percentage of net sales for royalty				40.00%
Royalties	578	400	$ 578	$ 578	$ 578	$ 578	$ 578	578	400	$ 856
Royalty expense	700	400						1,500	900
United States
Disaggregation of Revenue [Line Items]
Products which the company pays royalties					4	4
Products manufactured, marketed and distributed | drug					30
IGI Product
Disaggregation of Revenue [Line Items]
Company product sales, net	14,700	13,900						27,900	28,100
Net Of SRA Balance
Disaggregation of Revenue [Line Items]
Accounts receivable	$ 19,300	$ 33,700	$ 19,300	$ 19,300	$ 19,300	$ 19,300	$ 19,300	$ 19,300	$ 33,700

Revenues, Recognition and All_4

Revenues, Recognition and Allowances (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation of Revenue [Line Items]
Company product sales, net	$ 14,677	$ 13,912	$ 27,913	$ 28,120
Research and development services and other income	122	113	133	151
Revenue, net	16,249	16,432	30,794	34,095
Company product sales
Disaggregation of Revenue [Line Items]
Company product sales, net	14,677	13,912	27,913	28,120
Topical
Disaggregation of Revenue [Line Items]
Company product sales, net	7,888	8,558	15,795	16,153
Injectables
Disaggregation of Revenue [Line Items]
Company product sales, net	6,789	5,354	12,118	11,967
Contract manufacturing sales
Disaggregation of Revenue [Line Items]
Company product sales, net	$ 1,450	$ 2,407	$ 2,748	$ 5,824

Revenues, Recognition and All_5

Revenues, Recognition and Allowances (Details 2) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue from Contract with Customer [Abstract]
Gross Company product sales	$ 48,142	$ 66,744	$ 84,690	$ 121,044
Deduction to gross product sales:
Chargebacks and billbacks	21,449	44,090	38,364	74,105
Wholesaler fees for service	477	1,976	1,112	4,204
Sales discounts and other allowances	11,539	6,766	17,301	14,615
Total reduction to gross product sales	33,465	52,832	56,777	92,924
Company product sales, net	$ 14,677	$ 13,912	$ 27,913	$ 28,120

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 10,655	$ 8,231
Work in progress	944	616
Finished goods	8,434	8,532
Inventories reserve	(2,458)	(1,304)
Inventories, net	$ 17,575	$ 16,075

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property plant and equipment	$ 92,548	$ 76,722
Less accumulated depreciation and amortization	(9,258)	(8,367)
Property, plant and equipment, net	83,290	68,355
Land
Property, Plant and Equipment [Line Items]
Property plant and equipment	257	257
Building and improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment	17,474	8,613
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment	9,674	9,142
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment	4,059	3,244
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment	553	449
Construction in progress
Property, Plant and Equipment [Line Items]
Property plant and equipment	$ 60,531	$ 55,017

Property, Plant and Equipment_3

Property, Plant and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Property, Plant and Equipment [Line Items]
Depreciation expense			$ 1,133	$ 822
Interest costs capitalized			477	0
Construction in progress
Property, Plant and Equipment [Line Items]
Interest costs capitalized	$ 1,500	$ 700	2,800	1,200
Payroll costs	$ 700	$ 200	$ 1,100	$ 400

Debt (Details Textual)

Debt (Details Textual) - USD ($)	Jul. 16, 2018	Jun. 01, 2018	Apr. 27, 2018	Apr. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 22, 2014	Dec. 16, 2014
Debt Instrument [Line Items]
Partial extinguishment of equity component of Convertible 3.75% Senior Notes							$ 7,600,000
Partial extinguishment of Convertible 3.75% Senior Notes					$ 2,467,000	$ 0	2,467,000	$ 0
Qualified Institutional Buyers
Debt Instrument [Line Items]
Face amount of the Notes										$ 18,750,000	$ 125,000,000
Convertible Note 2019
Debt Instrument [Line Items]
Face amount of the Notes					$ 68,660,000		$ 68,660,000		$ 143,750,000
Stated interest rate					3.75%		3.75%		3.75%
Debt, transfer				$ 75,100,000
Non-cash interest expense				10,100,000	$ 2,500,000
Partial extinguishment of Convertible 3.75% Senior Notes				$ 75,100,000
Convertible Note 2019 | Convertible Notes Payable
Debt Instrument [Line Items]
Stated interest rate					3.75%		3.75%				3.75%
Debt, transfer			$ 75,100,000				$ 75,100,000
Partial extinguishment of Convertible 3.75% Senior Notes			$ 75,100,000
Convertible Note 2023
Debt Instrument [Line Items]
Face amount of the Notes					$ 75,090,000		$ 75,090,000
Stated interest rate					4.75%		4.75%		4.75%
Partial extinguishment of equity component of Convertible 3.75% Senior Notes							$ (7,602,000)
Convertible Note 2023 | Convertible Notes Payable
Debt Instrument [Line Items]
Stated interest rate			4.75%		4.75%		4.75%
Debt, transfer			$ 75,100,000				$ 75,100,000
Initial conversion price (dollars per share)			$ 224.71
Settlement conversion price (dollars per share)			$ 280.90
Debt issuance costs			$ 1,600,000
Unamortized discount			$ 19,000,000
Interest rate, effective percentage			12.10%
Term Loan 2021
Debt Instrument [Line Items]
Face amount of the Notes		$ 25,000,000			$ 15,000,000		$ 15,000,000
Debt issuance costs		500,000
Unamortized discount		$ 400,000
Interest rate, effective percentage		13.56%
Covenant, minimum cash balance		$ 5,000,000
Proceeds from lines of credit		$ 15,000,000
Floor interest rate		2.00%
London Interbank Offered Rate (LIBOR) | Term Loan 2021
Debt Instrument [Line Items]
Basis spread on variable rate		9.00%
Subsequent Event | Term Loan 2021
Debt Instrument [Line Items]
Proceeds from lines of credit	$ 10,000,000

Debt (Details)

Debt (Details) - USD ($)	Jun. 30, 2018	Jun. 01, 2018	Dec. 31, 2017
Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes	$ 158,750,000		$ 143,750,000
Less unamortized discounts and debt issuance costs	28,871,000		22,773,000
Carrying amount of the Notes	129,879,000		120,977,000
Convertible Note 2019
Debt Instrument [Line Items]
Face amount of the Notes	68,660,000		143,750,000
Convertible Note 2019 | Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes	68,660,000		143,750,000
Term Loan 2021
Debt Instrument [Line Items]
Face amount of the Notes	15,000,000	$ 25,000,000
Term Loan 2021 | Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes	15,000,000		0
Convertible Note 2023
Debt Instrument [Line Items]
Face amount of the Notes	75,090,000
Less unamortized discounts and debt issuance costs	400,000
Convertible Note 2023 | Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes	$ 75,090,000		$ 0

Debt (Details 1)

Debt (Details 1) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Debt Instrument [Line Items]
Debt partial extinguishment		$ 2,467	$ 0	$ 2,467	$ 0
Debt discount amortization				4,422	4,183
Debt financing amortization				505	456
Convertible Notes Payable
Debt Instrument [Line Items]
Interest expense		6,453	3,705	10,395	7,334
Convertible Note 2019
Debt Instrument [Line Items]
Debt partial extinguishment	$ 75,100
Convertible Note 2019 | Convertible Notes Payable
Debt Instrument [Line Items]
Interest expense		878	1,347	2,226	2,695
Debt partial extinguishment		2,467	0	2,467	0
Debt discount amortization		1,571	2,126	3,910	4,183
Debt financing amortization		191	232	446	456
Term Loan 2021 | Convertible Notes Payable
Debt Instrument [Line Items]
Interest expense		141	0	141	0
Debt discount amortization		14	0	14	0
Debt financing amortization		17	0	17	0
Convertible Note 2023 | Convertible Notes Payable
Debt Instrument [Line Items]
Interest expense		634	0	634	0
Debt discount amortization		498	0	498	0
Debt financing amortization		$ 42	$ 0	$ 42	$ 0

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Line Items]
Goodwill	$ 445,000	$ 471,000	$ 446,000
Impairment losses, goodwill	0
Alveda Pharmaceuticals
Goodwill [Line Items]
Goodwill	$ 400,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Goodwill [Roll Forward]
Goodwill beginning balance	$ 471	$ 446
Goodwill balance at December 31, 2016	(26)	25
Goodwill ending balance	$ 445	$ 471

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Details 1) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, accumulated amortization	$ (7,832)		$ (6,457)
Total	52,930		56,017
Indefinite-lived Intangible Assets [Line Items]
Intangible assets gross carrying amount	60,762		62,474
Intangible assets net carrying amount	52,930		56,017
In process research and development (IPR&D)
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	17,831		18,311
Trademarks and Technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	39,294		40,380
Finite-lived intangible assets, accumulated amortization	(6,875)		(5,684)
Total	$ 32,419		34,696
Weighted average remaining amortization period	12 years 4 months 24 days	12 years 9 months 18 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	$ 3,637		3,783
Finite-lived intangible assets, accumulated amortization	(957)		(773)
Total	$ 2,680		$ 3,010
Weighted average remaining amortization period	7 years 7 months 3 days	7 years 10 months 24 days

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets (Details 2) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance	$ 56,017
Amortization	(1,550)	$ (1,396)
Finite-lived intangible assets ending balance	52,930
Indefinite-lived Intangible Assets [Roll Forward]
Loss on impairment	(22)	$ 0
In process research and development (IPR&D)
Indefinite-lived Intangible Assets [Roll Forward]
Indefinite-lived intangible assets, beginning balance	18,311
Loss on impairment	(15)
Foreign currency translation	(465)
Indefinite-lived intangible assets, ending balance	17,831
Trademarks and Technology
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance	34,696
Amortization	(1,363)
Impairment of Intangible Assets, Finite-lived	(7)
Foreign currency translation	(907)
Finite-lived intangible assets ending balance	32,419
Customer relationships
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance	3,010
Amortization	(187)
Foreign currency translation	(143)
Finite-lived intangible assets ending balance	$ 2,680

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets (Details 3) $ in Thousands	Jun. 30, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2018 (remainder of the year)	$ 1,550
2,019	3,099
2,020	3,099
2,021	3,099
2,022	3,099
2,023	3,099
Thereafter	18,054
Total	$ 35,099

Goodwill and Intangible Asset_7

Goodwill and Intangible Assets (Details 4)	6 Months Ended
	Jun. 30, 2018
Trademarks and Technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	15 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	10 years

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Textual) - USD ($) $ in Millions	May 25, 2016	May 29, 2010	Apr. 12, 2010	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Stock Based Compensation Details [Line Items]
Shares available for grant (in shares)								20,000,000
Unrecognized compensation costs				$ 2		$ 2
Employee Stock Option
Stock Based Compensation Details [Line Items]
Number of options issued (in shares)						679,785
Number of options forfeited (in shares)						200,490
Shares of common stock options outstanding (in shares)				4,768,105		4,768,105		4,299,810
Employee Stock Option
Stock Based Compensation Details [Line Items]
Compensation expense				$ 0.3	$ 0.6	$ 0.8	$ 1.2
Restricted Stock
Stock Based Compensation Details [Line Items]
Compensation expense				0.1	$ 0.2	0.3	$ 0.5
RSUs outstanding (in shares)								89,003,000
Unrecognized compensation costs				$ 0.8		$ 0.8
Restricted Stock | Minimum
Stock Based Compensation Details [Line Items]
Vesting period						1 year
Restricted Stock | Maximum
Stock Based Compensation Details [Line Items]
Vesting period						3 years
Director Stock Option Plan - 1999
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)								1,975,000
Number of options issued (in shares)								2,634,798
Number of options forfeited (in shares)						807,782
Vesting period						1 year
Maximum term						10 years
Shares of common stock options outstanding (in shares)				500,000		500,000		500,000
Director Stock Option Plan - 1999 | Employee Stock Option
Stock Based Compensation Details [Line Items]
Shares available for grant (in shares)								147,984
1999 Stock Incentive Plan
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)				3,200,000		3,200,000
Number of options issued (in shares)						2,892,500
Vesting period						4 years
Maximum term						10 years
Shares of common stock options outstanding (in shares)				0		0
FMV common stock options granted (as a percent)						100.00%
Service period						1 year
Plan 2,009
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)		5,000,000
Number of options forfeited (in shares)	2,500,000
Shares of common stock options outstanding (in shares)				2,932,846		2,932,846		3,038,634
Shares available for grant (in shares)				1,493,960		1,493,960		1,422,020
Additional shares authorized (in shares)	2,000,000		2,000,000
Maximum number of shares to any individual (in shares)		1,000,000
Plan 2009 | Employee Stock Option
Stock Based Compensation Details [Line Items]
Shares available for grant (in shares)				98,098		98,098		249,052,000
Plan 2009 | Restricted Stock
Stock Based Compensation Details [Line Items]
RSUs outstanding (in shares)				24,376		24,376		99,626,000
Plan 2,016
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)	4,000,000
Shares of common stock options outstanding (in shares)				49,667		49,667		761,176,000
Shares available for grant (in shares)				2,935,736		2,935,736		1,526,857
Maximum number of shares to any individual (in shares)	1,000,000
Plan 2016 | Common Stock
Stock Based Compensation Details [Line Items]
Shares of common stock options outstanding (in shares)				1,335,529		1,335,529
Plan 2016 | Restricted Stock
Stock Based Compensation Details [Line Items]
RSUs outstanding (in shares)				174,472		174,472
Plan 2016, Plan 2009 And Director Plan | Employee Stock Option
Stock Based Compensation Details [Line Items]
Shares of common stock options outstanding (in shares)				4,768,105		4,768,105		4,299,810,000
Director Plan And The 2009 Plan
Stock Based Compensation Details [Line Items]
Intrinsic value of options outstanding				$ 4.5		$ 4.5
Intrinsic value of options exercisable				$ 4.3		$ 4.3

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Stock Based Compensation [Line Items]
Expected dividends	0.00%	0.00%
Risk-free rate	2.36%	1.55%
Minimum
Stock Based Compensation [Line Items]
Expected volatility	60.50%	58.00%
Expected term (in years)	3 years 2 months 12 days	3 years 2 months 12 days
Maximum
Stock Based Compensation [Line Items]
Expected volatility	62.30%	69.70%
Expected term (in years)	3 years 3 months 18 days	3 years 3 months 18 days

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details 1) - Employee Stock Option	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Number of Options
Number of options outstanding, balance beginning (in shares) | shares	4,299,810
Number of options issued (in shares) | shares	679,785
Number of options exercised (in shares) | shares	(11,000)
Number of options forfeited (in shares) | shares	(200,490)
Number of options expired (in shares) | shares	0
Number of options outstanding, balance ending (in shares) | shares	4,768,105
Number of options exercisable (in shares) | shares	3,546,700
Weighted Average Exercise Price
Shares outstanding exercise price, balance beginning (in dollars per share) | $ / shares	$ 5.09
Issued, exercise price (in dollars per share) | $ / shares	3.29
Exercised, exercise price (in dollars per share) | $ / shares	1.08
Forfeited, exercise price (in dollars per share) | $ / shares	7.02
Expired, exercise price (in dollars per share) | $ / shares	0
Shares outstanding exercise price, balance ending (in dollars per share) | $ / shares	4.76
Exercisable, exercise price (in dollars per share) | $ / shares	$ 4.63

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details 2)	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options outstanding (in shares) | shares	4,768,105
Weighted average exercise price (in dollars per share)	$ 4.76
Weighted average remaining contractual life	6 years 3 months 1 day
Stock options exercisable (in shares) | shares	3,546,700
Weighted average exercise price (in dollars per share)	$ 4.63
$0.55 - $1.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	0.55
Range of exercise prices (in dollars per share)	$ 1.50
Stock options outstanding (in shares) | shares	1,735,000
Weighted average exercise price (in dollars per share)	$ 1.06
Weighted average remaining contractual life	3 years 7 months 10 days
Stock options exercisable (in shares) | shares	1,735,000
Weighted average exercise price (in dollars per share)	$ 1.06
$1.51 - $5.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	1.51
Range of exercise prices (in dollars per share)	$ 5.50
Stock options outstanding (in shares) | shares	873,469
Weighted average exercise price (in dollars per share)	$ 3.18
Weighted average remaining contractual life	8 years 6 months 8 days
Stock options exercisable (in shares) | shares	202,166
Weighted average exercise price (in dollars per share)	$ 2.75
$5.51 - $10.67
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	5.51
Range of exercise prices (in dollars per share)	$ 10.67
Stock options outstanding (in shares) | shares	2,159,636
Weighted average exercise price (in dollars per share)	$ 8.38
Weighted average remaining contractual life	7 years 5 months 13 days
Stock options exercisable (in shares) | shares	1,609,534
Weighted average exercise price (in dollars per share)	$ 8.72

Stock-Based Compensation (Det_5

Stock-Based Compensation (Details 3) - Restricted Stock Units (RSUs)	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Number of RSUs
Non-vested balance at beginning of period (in shares) | shares	188,629
Shares granted (in shares) | shares	122,949
Shares vested (in shares) | shares	(101,607)
Shares forfeited (in shares) | shares	(11,123)
Non-vested balance at end of period (in shares) | shares	198,848
Weighted Average Exercise Price
Weighted average exercise price, non-vested balance beginning (in dollars per share) | $ / shares	$ 8.27
Shares granted - weighted average exercise price (in dollars per share) | $ / shares	3.36
Shares vested - weighted average exercise price (in dollars per share) | $ / shares	9.07
Shares forfeited - weighted average exercise price (in dollars per share) | $ / shares	7.21
Weighted average exercise price, non-vested balance ending (in dollars per share) | $ / shares	$ 4.88

Income Taxes (Details Textual)

Income Taxes (Details Textual) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)affiliate	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Income Tax Examination [Line Items]
Income tax expense	$ 23	$ 23	$ 47	$ 106
Effective income tax rate reconciliation, percent	0.20%	2.60%	0.30%	589.00%
Number of foreign affiliates subject to tax in Estonia | affiliate			1
Tax rate for earnings and profits as they are generated			0.00%
Remeasurement at new rate, percent			21.00%
Operating loss carryforwards					$ 41,700
Change in ownership percent					50.00%
Ownership change (greater than)					5.00%
Minimum
Income Tax Examination [Line Items]
Tax rate for earnings and profits that are distributed to shareholders			14.00%
Tax rate applied to dividends			14.00%
Maximum
Income Tax Examination [Line Items]
Tax rate for earnings and profits that are distributed to shareholders			20.00%
Tax rate applied to dividends			20.00%
Not Subject to Limitations | Subsequent To Change Date In 2010
Income Tax Examination [Line Items]
Operating loss carryforwards					$ 23,100
Subject to Limitations | Minimum
Income Tax Examination [Line Items]
Operating loss carryforwards					1,000
Subject to Limitations | Maximum
Income Tax Examination [Line Items]
Operating loss carryforwards					$ 2,300
Alternative Minimum Tax Carryover
Income Tax Examination [Line Items]
Credit receivable	$ 100		$ 100

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Other Income and Expenses [Abstract]
Capital expenditures	$ 2,476	$ 1,947
Payroll	1,483	1,580
Professional fees	1,284	546
Interest expense	763	240
Clinical studies	603	596
Royalties	578	856	$ 400
Medicaid and Medicare	542	1,487
Inventory and Supplies	460	58
Rebates	332	83
Income Tax	60	58
Other	688	650
Accrued expenses	$ 9,269	$ 8,101	$ 9,166

Legal and U.S. Regulatory Pro_2

Legal and U.S. Regulatory Proceedings (Details) $ in Millions	Oct. 20, 2017USD ($)drug	Jun. 30, 2018druglegal_actiongeneric_manufacturer_defendantlawsuit
Loss Contingencies [Line Items]
Number of legal actions | legal_action		3
Anti-Trust Lawsuit
Loss Contingencies [Line Items]
Number of putative class action antitrust lawsuits		12
Loss contingency, number of defendants | generic_manufacturer_defendant		34
Number of drugs involved | drug		29
Stayma
Loss Contingencies [Line Items]
Number of drugs involved | drug	2
Damages sought | $	$ 1.7
Opt Out | Anti-Trust Lawsuit
Loss Contingencies [Line Items]
Number of putative class action antitrust lawsuits		1
Loss contingency, number of defendants		35
Number of drugs involved		30
Motion To Dismiss | Anti-Trust Lawsuit
Loss Contingencies [Line Items]
Number of putative class action antitrust lawsuits		3

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2018	Nov. 12, 2018
Subsequent Event [Line Items]
Debt partial extinguishment		$ 2,467,000	$ 0	$ 2,467,000	$ 0
Subsequent Event
Subsequent Event [Line Items]
Shelf offering amount, suspended	$ 50,000,000
Reclassification of debt, net carrying value	$ 24,200,000
Ares Credit Facility | Ares Capital Management | Subsequent Event
Subsequent Event [Line Items]
Letter of commitment letter outstanding							$ 120,000,000
Revolver 2022 | Ares Capital Management | Subsequent Event
Subsequent Event [Line Items]
Letter of commitment letter outstanding							$ 25,000,000
Revolver 2022 | London Interbank Offered Rate (LIBOR) | Subsequent Event
Subsequent Event [Line Items]
Stated interest rate							3.75%
Term Loan 2023 | Ares Capital Management | Subsequent Event
Subsequent Event [Line Items]
Letter of commitment letter outstanding							$ 80,000,000
Term Loan 2023 | London Interbank Offered Rate (LIBOR) | Subsequent Event
Subsequent Event [Line Items]
Stated interest rate							8.75%
2023 Delayed Draw Term Loan | Ares Capital Management | Subsequent Event
Subsequent Event [Line Items]
Letter of commitment letter outstanding							$ 15,000,000
Term Loan 2021 | Forecast
Subsequent Event [Line Items]
Repayments of debt						$ 25,000,000
December 2019 Note | Forecast
Subsequent Event [Line Items]
Debt partial extinguishment						$ 68,700,000